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Lung cancer is the largest cause of cancer-related mortality worldwide and is the second most 
common cancer in New Zealand. By disproportionality impacting Māori and those who are 
most vulnerable in our community, lung cancer is a significant burden to New Zealand’s health 
system. 
 
Despite advancements in lung cancer treatment, relapse remains common in patients 
undergoing therapy. In recent years, our understanding of the drug resistance mechanisms that 
lead to relapse has been challenged by the discovery of the phenomenon of drug tolerance 
driven by a rare subpopulation of cells called “drug tolerant persisters” (DTPs). A growing 
body of literature suggests that non-genetic mechanisms allow DTPs to change their identity 
to evade therapy by assuming a lung progenitor cell phenotype. We aimed to investigate the 
role of lung progenitor and stem cell genes in DTPs induced by three distinct targeted agents, 
and to identify genes as markers to determine whether DTPs exist prior to treatment or are 
induced upon addition of drug.  
 
We generated DTPs in PC9, H3122 and H358 lung cancer cell lines with which contain 
oncogenic mutations in EGFR, ALK and KRAS, respectively. We found that the stem cell 
genes OCT3/4 and NANOG were upregulated by 4-fold (P<0.0005) and 2.5-fold (P<0.005) 
respectively in PC9 DTPs and by 6-fold (P<0.005) and 5-fold (P<0.0005) in respectively in 
H358 DTPs. SOX2, another stem cell gene, was found to be upregulated by 13-fold (P<0.005) 
in H3122 DTPs. Furthermore, our findings suggest that DTPs gain pluripotency by 
dedifferentiating back to a progenitor lung cell state, with the expression of the surfactant genes 
SFTPC and SFTPD being upregulated 5-fold (P<0.005), and 2.5-fold (P<0.05) in PC9 DTPs, 
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2-fold (P<0.05) and 5-fold (P<0.005) in H3122 DTPs and 5-fold (P<0.0005) and 9-fold 
(P<0.0005) in H358 DTPs respectively. Significantly, we identified AQP4 to be consistently 
upregulated in all three cell lines by at least 5-fold. AQP4 is a cell surface marker and thus will 
allow future studies to isolate DTPs from treated and untreated cell populations to determine 
whether DTPs are pre-existing or induced. 
 
The information generated throughout this project has provided insight into the establishment 
of the DTP phenotype, which will inform future studies to exploit these findings. By 
understanding the mechanisms that underpin drug tolerance in lung cancer, it is hoped that we 
will eventually be able to prevent drug tolerance and the subsequent development of stable 
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Lung cancer represents the single largest cause of cancer-related mortality worldwide, 
accounting for an estimated 1.8 million deaths in 2020 and is thus at the forefront of cancer 
research3. It is the second most common cancer in New Zealand and impacts thousands of 
families each year, with a dramatically high mortality rate that disproportionality impacts the 
most vulnerable members in our communities4. Lung cancer accounts for approximately 1,780 
deaths annually in New Zealand, with over 350 of these deaths affecting Māori, a figure that 
grossly over-represents the Māori population4. Therefore, research into this disease is 
significantly important to New Zealand and its peoples5.  
 
There are two broad types of lung cancer, non-small cell lung cancer (NSCLC) and small cell 
lung cancer (SCLC), making up 85% and 15% of lung cancers respectively (see Figure 1)1, 2. 
Research into the most common form of NSCLC, lung adenocarcinoma (LUAD)1, 2 is at the 
forefront to generate therapies, known as “targeted therapies,” that specifically focus on the 
underlying causes behind LUAD. Despite dramatic initial results, a large proportion of LUAD 
patients treated with targeted therapies relapse following treatment, evidenced by high 
mortality rates6. This persistently poor outcome is largely due to a development of resistance 






In recent years, our current understanding of resistance to targeted therapies has been 
challenged by the discovery of a rare subpopulation of so-called “drug tolerant persisters 
(DTPs)”8. Increasingly, evidence suggests that this small population of slow-cycling cells 
greatly contribute to relapse through their ability to survive treatment despite high 
concentrations of targeted therapies8. Recent reports suggest that the emergence of DTPs is not 
specific to LUAD patients but is present in other cancers such as melanoma9-11, glioblastoma12, 
gastric13 and ovarian cancers14 and thus is of particular significance in the fight against the 
global cancer pandemic.  
 
1.2 Drivers of Lung Cancers:  
Physiologically, cells require tight pathway control to ensure that they only grow and 
proliferate under the right conditions15. Alterations to these pathways often result in 
uncontrolled survival and proliferation, underpinning cancer development16. The basis of 
cancer development can be described as the uneven ratio between genes in pathways that drive 
cancer, called oncogenes, and genes in the pathways that suppress cancers, known as tumor 
suppressor genes16.  
Figure 1: Subtypes of lung cancer. Lung cancer may be broadly separated into two groups, non-small 
lung cancer (NSCLC), which makes up 85% of all lung cancers, and small cell lung cancers (SCLC), 
which makes up the remaining 15% of lung cancers1, 2. NSCLC maybe further divided into lung 
adenocarcinoma (LUAD), which makes up 50% of NSCLCs, and small cell carcinoma (SCC) which 




One of the most common oncogenic pathways implicated in LUAD is the mitogen activated 
protein kinase/extracellular signal-regulated kinase pathway (MAPK/ERK pathway)7. This 
signaling cascade consists of several tyrosine kinases that use phosphate exchange to mediate 
signaling for many physiological processes including cell survival and proliferation17-19. 
 
Frequently, one or more steps (referred to as “nodes”) of the MAPK/ERK pathway become 
dysregulated, often resulting in its constitutive activation. This causes constant survival and 
proliferation signals that result in carcinogenesis and forms the basis of cancers such as 
LUAD7. While an in-depth investigation into the involvement of the MAPK/ERK pathway in 
LUAD is out of the scope of this thesis, common mutations involved in LUAD are summarized 
below in Figures 2 and 3. The discovery that these nodes are the primary drivers of cancers 
such as LUAD has allowed researchers to investigate and develop methods of combatting these 
alterations.  
Figure 2: Prevalence of common driver mutations in the MAPK/ERK pathway in lung 
adenocarcinoma. 
KRAS is the most prevalent driver mutation in LUAD, 
present in 20-30% of LUADs20. Mutations in the 
MAPK/ERK receptor tyrosine kinase EGFR are the 
second most prevalent mutation in LUAD, present in 
around 16% of patients with LUAD21. BRAF 
mutations consists of 10% of LUAD patients20. The 
EML4-ALK fusion is present in 1-7% of LUAD 
patients and works by mimicking the receptor tyrosine 
kinase 20.Other mutations in the MAPK/ER pathway 
are either extremely rare, (for example MEK22), or 
have not been reported (such as ERK23. Image created 
using BioRender.com. Original work, Davis 2021 
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1.3 Targeted Therapies:  
Subsequent to the elucidation of nodes in oncogenic pathways such as the MAPK/ERK 
pathway, much work has been done to generate inhibitors that switch off the activation of these 
nodes that drive cancers such as LUAD7. This led to the generation of a class of drugs known 
as “targeted therapies” 24. First used in microbiology, the term “targeted therapies” was 
originally used to describe specific chemicals that target specific microorganisms. The 
definition has now expanded to incorporate specific cancer therapeutics that target specific 
mutations in oncogenes known to drive cancers24. As nearly two-thirds of NSCLC patients 
have identifiable oncogenic mutations, targeting these mutations is extremely important7. 
 
The use of targeted therapies began with the remarkable development of trastuzumab for HER2 
positive breast cancers which targets the RTK Human Epidermal Receptor 2 (HER2)25-27. 
Trastuzumab remains the frontline treatment for HER2-positive breast cancers today28. 
Following the development of trastuzumab, the use of targeted therapies has expanded to target 
many oncogenes, including EGFR in LUAD (see Figure 3). This was first developed by Ward 
and colleagues in 1994 by using an ATP analog which competitively binds to the ATP-binding 
pocket of EGFR, preventing its activation29. While initially not clinically significant, it later 
achieved relevance with the production of gefitinib, the first reversible EGFR inhibitor 
approved for use by the FDA30. Significant to New Zealand scientific history is the 
development of the first irreversible EGFR inhibitor to enter clinical trial, canertinib, by the 
Auckland Cancer Research Centre31. Despite failing phase II trials in 200332, canertinib paved 
the way for second generation EGFR inhibitors, such as afatinib (BIBW 2992)33 and eventually 
for third generation EGFR inhibitors such as the highly successful osimertinib34.  
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In the wake of these successful EGFR inhibitors, many other nodes of the MAPK/ERK 
pathway are now able to be inhibited using targeted therapies such as crizotinib successfully 
inhibited the EML4-ALK fusion protein (see Figure 3), and was FDA approved in 201135. 
Mutations in RAS however (see Figure 3) remained “undruggable” until the recent 
development of inhibitors that target KRASG12C, a KRAS mutant with glycine to cysteine 
change at residue 1236, and the most common RAS mutation in NSCLC occurring in 7.4% of 
patients37. Dramatically, recent innovations in targeted therapy research has led to the 
development of two novel inhibitors of KRASG12C, MRTX84938 and sotorasib (AMG 510)39, 
which provide a promising option for the treatment of KRAS mutant cancer patients. In spite 
of these developments, LUAD remains as a considerable issue globally, largely due to the 
development of resistance mechanisms in LUAD against targeted therapies. 
 
Figure 3: Simplified MAPK/ERK pathway. Receptor Tyrosine Kinases (RTKs), such as EGFR, 
mediate ligand binding and activation of the MAPK pathway, resulting in a phosphate signaling via a 
kinase cascade, mediating signaling via extracellular signal-regulated kinase (ERK) which signals for 
proliferation and survival. The MAPK/ERK pathway is commonly mutated in LUAD, driver its 
progression through proliferative signaling and thus is the target for many targeted therapies, 
including Crizotinib, which targets the EML4-ALK fusion protein, EGFR inhibitors, such as 
osimertinib, and KRASG12C inhibitors, such as sotorasib. Image created using BioRender.com. 
Original work, Davis 2021 
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1.4 Resistance to Targeted Therapies: 
Despite the initial success of targeted therapies in LUAD, it was rapidly realized that relapse 
was common in patients receiving these drugs40, 41. Early case reports of resistance to targeted 
therapies emerged in 2015 in response to gefitinib and erlotinib treated LUAD; the initial cause 
of resistance being a novel threonine to methionine mutation at position 790 in the EGFR 
protein (T790M)40, 41. Resistance and relapse have since become an almost indefinite fate 
regardless of the targeted therapy, with resistance even hampering the impacts of MRTX849 
and AMG 510 treatment despite being in their clinical infancy42. 
 
For years, it was widely accepted that the cause of the reemergence of LUAD after targeted 
therapy treatment was almost solely due to intrinsic resistance mechanisms43. However, recent 
evidence paints this story of resistance in a much more complex light43-45. Trever Bivona and 
Robert Doebele of the University of California and Colorado respectively classify the events 
leading to resistance in three categories: intrinsic resistance, resistance due to failure of 
pharmacokinetics, and tumor cell adaptation46.  
 
Intrinsic resistance refers to pre-existing resistance mutations found within a tumor that is then 
selected for under the pressure of targeted therapies46. Intrinsic resistance is largely driven by 
the genetic instability of the cancer genome which aids in the generation of a diverse gene pool 
in the tumor from which selection of cells harboring resistance mutations may occur47, 48.  
 
A second cause of resistance to targeted therapies is via pharmacokinetic failure46. 
Pharmacokinetic failure occurs when the targeted therapy fails to make contact or act on all of 
the cancer cells, leaving a residual pool of cells that lead to relapse46. While an in-depth analysis 
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of pharmacokinetic failure is beyond the scope of this thesis, it is important to understand that 
this is a major component of the diverse landscape of resistance to targeted therapy.  
 
Finally, tumor cell adaptation is the cells response to targeted therapy via adaptations to 
epigenetics8, metabolism49, cell dormancy50 and other mechanisms, such as adapting efflux 
methods51 to ensure that the cancer cell survives treatment. While largely overlooked, this 
recently categorized form of resistance is a considerable contributor to relapse and is thought 
to be driven by a small population of cells known as “drug tolerant persisters” (DTPs)8.” While 
similar to resistance, DTPs display behaviors distinct from intrinsic resistance which we will 
now define.  
 
1.5 Resistance vs Tolerance: 
Descriptions of cancer to students and the public often assume that the basis for this disease is 
rooted in genetic change. With this in mind, it is not surprising that mechanisms outside of 
classical mutational models are grossly overlooked in cancer research, even today43. However, 
as researchers move to target mutational changes that result in resistance, it is becoming clear 
that this game of “whack-a-mole” is more than mutational52. A major critique of the current 
field concerns the absence of distinct definitions to describe types of resistance mechanisms 
including resistance, tolerance and persistence, leading to confusion surrounding these 
phenomena44.  
 
Generally, “resistance” refers to a fixed state in which the cell cannot reversibly switch back 
to its former drug-vulnerable state44. This often occurs via the selection for a mutation (for 
example T790M in EGFR) in which the cell population cannot simply become “unmutated” 
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and therefore once a population of cancer cells become “resistant”, they will no longer respond 
to the targeted therapeutic indefinitely44.  
 
In most literature “tolerance” tends to DTPs display a reversible and non-genetic state of 
dormancy in order to “weather” treatment and are thus labeled as “drug tolerant” and 
“persistent”8. The definition of tolerance is far from universal; however, “DTPs” are cells able 
to survive treatment by entering a reversible state of dormancy, weathering treatment before 
repopulating the tumor and causing relapse to occur (see Figure 4)8, 10, 51. This response is non-
genetic in nature, with the parental population displaying the identical genotype to DTPs 
despite vastly differing phenotypes14.  
 
Figure 4: Tumour cell adaptation mediates resistance through a small population drug tolerant 
persisters (DTPs). DTPs are able to survive treatment by entering a reversible dormant state that allows 
them to “weather” treatment before causing release in patients. Figure adapted from Rambow et. al10. 
Image created using BioRender.com. Original work, Davis 2021.  
 
It has largely been suggested that the mechanism behind DTPs is phenotypic heterogeneity 
driven by a non-genetic basis such as sporadic fluctuations in gene expression. Often called 
“biological noise” it is caused by factors such as changes to epigenetic regulation within the 
cell as well as random shifts in regulatory and signaling pathways14, 53-56. While most biological 
noise does not impact the cell, some fluctuations have been shown to induce changes in gene 
expression and drive differences in phenotype57. This concept has been well categorized in 
genetics54-56, although its involvement in the field of cancer remains to be fully appreciated. A 
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recent investigation into biological noise in cancers utilized a Luria and Delbrück fluctuation 
analysis58 combined with a population-based RNA sequencing approach termed “MemorySeq” 
and determined that non-genetic fluctuations in gene expression are able to form distinct 
subpopulations that persist over multiple generations, despite having an identical genotype to 
their homologous parental population59. This is significant as this suggests that the generation 
and maintenance of a small population, such as DTPs, can occur through biological noise alone 
thus underpinning the theories surrounding the generation of DTPs59. 
 
1.6  Generation of a DTP Population:  
The generation of DTPs is spearheaded by two dominant theories under significant debate44. 
The first is where a pre-existing DTP (sometimes called “primed”60) population is present 
before treatment and is “selected” for under targeted therapy44 (see Figure 5). The majority of 
evidence generated in support of this hypothesis often follows the method of determining 
markers for DTPs and then searching for them back in the parental population prior to drug 
treatment. For example, in glioblastoma, DTPs are dependent on Notch and histone 
demethylase expression12. Liau and colleagues found that upregulation of these markers was 
present not only in the resulting DTPs, but also in a small population of slow-cycling cells prior 
to treatment, thus pointing to the generation of pre-existing DTP progenitors prior to 
treatment12. In a similar analysis, Shaffer et. al found that DTPs in melanoma may be 
categorized via high expression of EGFR, NGFR and AXL and that these markers were present 
in small populations of cells (termed “jackpot” cells) in the parental population. Shaffer et. al. 
was even able to use these markers to predict which parental cells are more likely to enter a 
DTP state following treatment, strongly suggesting that primed cells in the parental population 
are progenitors to DTPs9. Torre and colleagues used a similar approach to perform CRISPR 
screening for factors in the parental population that predicted the formation of DTPs60. They 
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discovered that cells became transiently primed toward DTPs through a number of pathways 
pre-treatment60. This suggests that the generation of DTPs is indeed pre-existing and a result 
of random non-genetic fluctuations in expression such as biological noise in the parental 
population. This is then selected for during treatment, resulting in the formation of DTPs 
(bottom of Figure 5)59, 60.  
 
Despite this evidence, many studies suggest that DTPs arise de novo during treatment8, 10, 11, 61. 
This theory involves the phenomenon of Lamarckian induction, which explains the non-genetic 
basis for generational adaptation to the environment and is dramatically overlooked in the 
context of cancer resistance and adaptation (see top of Figure 5)62, 63. In support of this 
mechanism, Rambow and colleagues found lineage markers characteristic of DTPs in 
melanoma were not present in the parental population, but their expression was induced de 
novo following treatment10. The DTP population shows remarkable plasticity to stress, 
displaying reversible phenotypic switching10 in an extremely rapid manner, indicating a direct 
induction response11. Induction of phenotypic switching is also dose dependent, showing a 
phenotype that is variable based on the environmental fluctuations, an observation that makes 
little sense outside the context of induction11, 14. Furthering this evidence is a remarkable 
observation in leukaemia, where an actual induction of changes to drug efflux was observed 
during treatment while transitioning to a DTP phenotype61. This induced change could not be 
selected for, supporting a model where a selection independent, drug-induced instructive mode 
of phenotypic switching occurs, thus supporting the hypothesis that Lamarckian induction 
generates the DTP population61. While seemingly trivial, determining when DTPs arise may 
provide significant insights into the mechanisms that underpin their existence, and will have 
dramatic impacts on any therapeutics developed, either directly by preventing the formation of 
DTPs or in advising dosing strategies for the administration of therapeutics. 
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Figure 5: Possible mechanisms behind the generation of drug tolerant persisters and the progression towards stable fixed resistance. There are two dominant 
theories surrounding the generation of DTPs, induction (above) represents the generation of de novo DTPs in dynamic response to treatment, and selection 
(below), where non-genetic fluctuations drive the formation of pre-existing DTPs which then survive treatment. Following the generation of DTPs, the 
population either reverts back to the parental phenotype or develops stable resistance through permanent non-genetic adaptations or late mutations. These 
cells are then able to expand and repopulate the tumour causing relapse. Image created using BioRender.com. Original work, Davis 2021
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1.7 Characterization of DTPs: What Makes a DTP a DTP? 
Debates into the origins of DTPs aside, the characterization of DTPs remains essential in 
furthering our understanding of this population. At the heart of what makes DTPs unique are 
global alterations to their epigenetic landscape8. This alteration is largely mediated through an 
increase in the expression of the histone demethylase KDM5A/RBP2/Jarid1A8, exhibiting 
histone demethylation on H3 histones at lysine 4 (H3K4)64. Since this discovery, a body of 
literature has grown to support the underpinning of DTPs through global changes in 
epigenetics9, 10, 12, 51, 60, 65, 66.  
 
This global epigenetic shift has a dramatic impact on the phenotype of the DTP, resulting in 
changes to the expression of many major signalling pathways66, 67. While the breadth of these 
changes appears to be vast, recent reports have determined that these alterations largely induce 
an upregulation in developmental and lineage pathways, as well as stem cell markers60, 66, 67. 
 
Early on, lineage association was largely associated with DTPs in melanoma cells, with much 
early work being carried out in this cancer type (see Table 1 below for gene information), with 
the melanoma lineage-associated gene NGFR9, 68 becoming a prominent marker for DTPs. In 
addition to this, DTPs in melanoma can be characterised by dramatic alterations to the 
dedifferentiation markers SOX10 and the upstream transcription factor MITF9, 10, 69. 
Confusingly, both MITFHIGH and MITFLOW populations appear to be characteristic of 
melanoma DTPs, thought to represent a number of stages present in DTP formation10. LUAD 
also shares a strong resemblance with a lineage phenotype, with the expression profile of DTPs 
resembling that of alveolar type 2 cells (AT2), a lung cell that has stem-like cell qualities67. 
This is consistent with the slow-cycling plastic DTP population8 and the multipotent nature of 
 25 
AT2 cells70, supporting the hypothesis that lineage pathways contribute to the formation of 
DTPs. 
 
As well as being highly associated with lineage markers, DTPs also express an array of stem 
cell markers, such as CD1338, CD248, CD7471, aldehyde dehydrogenase72, 73, CD4451, SOX251 
and SOX466 (see Table 1 for gene information). A global increase in NANOG signalling via 
AP-1 site binding74 is also found in DTPs9, suggesting changes in stem factors do impact 
signalling in the cell. This volume of evidence indicates that stem cell marker upregulation 
plays a significant role in forming the stem cell-like plastic phenotype found in DTPs. It is also 
thought that following their generation, the DTPs are further stabilized in their plastic state via 
the stem-like abilities of self-renewal, thus allowing for the maintenance of the DTP population 
throughout drug treatment14.  
 
In sum, the lineage and stem characteristics of DTPs display a state that is remarkably similar 
to a state of diapause75, a reversible embryonic survival program76. A recent study performed 
by Rehman and colleagues found that DTPs “unlock” these developmental programs during 
the formation of DTPs, causing the observed diapause-like phenotype75. While much of the 
characterisation of the mechanisms that underpin DTPs remains a mystery, these are significant 
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1.8 Exit from Drug Tolerance:  
Following the establishment and stabilization of DTPs, there are at least two distinct paths that 
DTPs follow (Figure 5). Several groups have noted that if cessation of drug treatment occurs 
(referred to as a “drug holiday”), the DTPs re-emerge from their dormant state and revert back 
into the phenotype of the parental drug-naïve cell population8, 51, 110. However, after an 
extended period of re-exposure, DTPs exhibit a permanently altered phenotype consistent with 
stable resistance8, 51, 110.  
 
Congruent with most theories surrounding DTPs, there is debate surrounding the generation of 
stable resistance, with some papers suggesting a permanent, epigenetically mediated transition 
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toward stable (irreversible) resistance9, and others positing that genetic instability within the 
DTP population generates a pool of cells from which resistance mutations (such as the well-
known EGFRT790M mutation8) can be generated8, 11, 14, 110. In reality it is likely to be a 
combination of both mechanisms, with a transition into a stable phenotype through epigenetics 
occurring while DTPs are existing as a reservoir of cells with poor DNA repair pathways11 are 
waiting for so called “late mutations (see Figure 5)110” to occur and enable stable resistance.  
 
1.9  Conclusion:  
In a recent Nature article the President of The Institute of Cancer Research, Paul Workman, 
remarked that cancer resistance is “the biggest problem that we face in cancer drug 
development”52. One major critique of modern cancer therapy is the emphasis on targeting the 
genetic basis of cancer cells and cells that proliferate rapidly, leaving slow-cycling and adaptive 
DTPs untouched43. Research into DTPs offers a novel avenue to prevent relapse via this 
population not only in LUAD, but in many cancers hampered by the emergence for DTPs. 
While much research has been done, there are significant gaps in our understanding of DTPs, 
as highlighted. In particular, research into both the generation and formation of DTPs, and 
whether they form pre-treatment or during treatment, is essential for understanding the 
mechanisms that underpin the formation of this population and any vulnerabilities that maybe 
exploited against them. This Honours project aims to generate a model of DTPs in a panel of 
lung adenocarcinoma cell lines with distinct driver mutations over the relatively short timepoint 
of 72 h.  Using this, the aim is then to investigate the involvement of relevant stem cell and 
lung lineage-associated factors in the emergence DTPs over 72 h. Once the involvement of 
these factors is demonstrated, we aim to identify whether these factors may be used as markers 
for DTPs in lung adenocarcinomas.  
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1.10 Hypothesis:  
We hypothesise that during treatment with mutation specific drug, DTPs emerge as a 
subpopulation of LUAD cancer cells that expresses stem cell-associated factors and lung 
lineage-associated genes at high levels.  
 
1.11 Aims and Objectives:  
We will test this hypothesis by generating DTPs in a panel of lung adenocarcinoma cell lines 
from which we will characterise the involvement of stem and progenitor cell factors. From 
these factors we aim to identify markers of DTPs, which may be used in future experiments to 
isolate DTPs in lung adenocarcinomas.   
 
This project can be broken into four aims:  
1. Determine the concentrations of mutation-specific targeted therapies required to 
generate a DTP cell population in each cell line model. 
2. Confirm the method of action of each mutation-specific targeted therapy in cell line 
models. 
3. Determine whether stem cell and lung lineage-associated factors are commonly 
upregulated in DTPs generated in response to mutation specific drugs 
4. Determine markers that can be used to determine whether DTPs are generated prior to 
treatment, during treatment or post treatment in response to targeted therapy.  
The completion of the above aims will further the field of DTP research in LUAD by providing 
directions for future research into stem and lineage factor mediated transition into a DTP 
phenotype, and will determine when this transition occurs. This may allow for future research 
to use this knowledge to find and exploit vulnerabilities within this transition, and may allow 
us to target this population and prevent relapse due to DTPs. 
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2 Materials and Methods: 
2.1 Mammalian Cell Culture: 
 
2.1.1 Cell Lines: 
A panel of lung adenocarcinoma cell lines with driver mutations in the MAPK pathway were 
used as in vitro models to generate DTPs. See Table 3 below:  
 
Table 3: Panel of Cell Lines Used in Experiments 
Cell Line  RRID Source  Species of 
Origin  
Cancer Type Driver 
Mutation 
PC9 CVCL_B260 ATCC Human Lung 
adenocarcinoma  
EGFR T790M 
H3122 CVCL_AY53 As a gift from 
A/Prof John 














CVCL_4358 As a gift from Dr 
Gabi Dachs, Dept 
of Pathology, UoC 
 




2.1.2 Cell Culture: 
All cells were cultured in 75 cm2 cell culture flasks using GlutaMAX RPMI-1640 growth 
medium (ThermoFisher) with the exception of the H358 cell line, which was cultured in RPMI-
1640 from ATCC for warranty reasons. RPMI-1640 growth media was supplemented with 
10% foetal bovine-serum (FBS) (Moregate) added for culture. Throughout culture, all cells 
were incubated in a humidified atmosphere at 37℃ in 5% carbon dioxide in air. All cell lines 
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were routinely tested for mycoplasma using the Mycoalert kit (Lonza) and were maintained at 
a low passage number (maximum of mid-twenties).  
 
2.1.3 Cell Maintenance:  
To ensure that cells remained in log phase and to obtain cells for downstream experiments, 
cells were sub-cultured once they had reached a confluency of approximately 90%. This was 
achieved by removing the RPMI-1640 growth medium, washing the cells with 10 mL of 
phosphate buffered saline (PBS), and finally trypsinizing the cells using 2 mL of pre-warmed 
trypsin (0.25% v/v) with phenol red. Once the cells had lifted into suspension, the trypsin was 
neutralised in 8 mL RPMI-1640 growth medium containing FBS. 
 
Cells were then used for further experiments and sub-cultured by diluting the cells 1:10 for 
PC9, LL2 and H3122 cell lines, and 1:5 for the H358 cells in RPMI-1640 growth medium. For 
subculture, cells were transferred into fresh 75 cm2 cell culture flasks and the passage number 
was recorded. For further experiments, cells were transferred into a 45 mL Falcon tube and 
were centrifuged at 250 x g for 5 min, resulting in a cell pellet. Remaining medium was then 
removed and replaced with 5-10 mL fresh RPMI-1640 growth medium.  
 
2.1.4 Viable Cell Enumeration: 
Cells were counted by thoroughly mixing 10 µL of cell suspension with 10 µL trypan blue. 10 
µL of this mix was then loaded onto a hemocytometer. Live cells were distinguished from dead 
cells as having clear cytoplasm due to their intact outer cell membrane, preventing the uptake 
of trypan blue into the cytoplasm, while dead cells, which do not have an intact outer cell 
membrane, uptake the dye readily into their cytoplasm. This allowed us to distinguish and 
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discount dead cells from live cell counts, allowing for the cell viability and total live cell count 
to be performed. This was calculated by counting and averaging the cells present in 3 grids of 
the hemocytometer, with one grid representing the cells counted×104 cells/ml. 
 
2.2 Cell Imaging:  
Cells were imaged following cell culture and drug treatments during each experiment. Cells 
were imaged via digital inverted bright-field microscopy at 4x magnification on an EVOS XL 
Core Imaging System (ThermoFisher Scientific). Images were saved as TIFF files for further 
analysis.  
 
2.3 Proliferation Assays:  
2.3.1 Cell Seeding:  
Following cell culture, maintenance, and viable enumeration (sections 2.1.2-2.1.4), 96 well 
plates were plated with cells. PC9 cells were seeded at a density of 500 cells per well, while 
H3122, H358 and LL2 cells were seeded at 2,000 cells per well. The first column of the 96 
well plate was left empty at this point to serve as a media only control in future (see Figure 6).  
 
2.3.2 Drug treatment:  
Cells were drugged 24 h after plating with their mutation-specific targeted therapy. PC9 cells 
were drugged with Osimertinib (AZD9291), H3122 cells were drugged with Crizotinib (PF-
02341066), and H358 and LL2 cells with Sotorasib (AMG510). Crizotinib was provided by 
A/Prof John Ashton; all other drugs were obtained from Selleckchem. The 96-well plates were 
set out as in Figure 6, with the highest concentration for PC9, H3122 and LL2 cells at 50 µM, 
and H358 cells at 30 µM. A 3-fold dilution series was prepared to generate a spectrum of doses. 
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DMSO controls were provided at the same concentration as the maximum concentration of 
drug used and medium only and untreated cell controls were also included.  
 
Figure 6: Plate layout for proliferation assays. Image created using BioRender.com. 
Original work, Davis 2021.  
 
Proliferation assay plates were then incubated for 72 h before medium was removed, and plates 
were frozen at -80 ˚C.  
 
2.3.3 SYBR Preparation and Analysis: 
Frozen plates were thawed at room temperature for 1 h. SYBR Green I (ThermoFisher 
Scientific) was then added at a concentration of 1:8,000 to lysis buffer (see appendix II). 200 
µL of SYBR green mix was then added to each well and the plates were wrapped in foil to 
protect from light and were then incubated overnight at 4 ℃. Plates were then read with a 
Victor fluorimeter set at 485 nm excitation/535 nm emission. For analysis, sample wells were 
normalized to DMSO control wells and data was graphed using GraphPad Prism 9 for MacOS 
(v. 9.0.1).  
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2.4 Western Blotting:  
2.4.1 Cell Seeding:  
Following cell culture, maintenance and viable cell enumeration (see sections 2.1.2-2.1.4), PC9 
and H3122 cells were seeded in 10 cm cell culture dishes at 5x106 cells per 10 cm dish, while 
H358 cells were seeded at 2x105 cells per 10 cm dish. 
 
2.4.2 Cell Treatments: 
Cells were drugged, according to Figure 7, 24 h after cell plating according to the 
concentrations required to generate a population of DTPs based on the proliferation assays 
performed prior (section 2.3). 2 µM, 5 µM, and 10 µM concentrations of Osimertinib were 
used to generate DTPs in PC9 cells, 5 µM, 10 µM and 15 µM concentrations were used to 
generate DTPs in H3122 cells using Crizotinib and 1 µM, 5 µM and 10 µM concentrations 
Sotorasib were used to generate DTPs in H358 cells. Each treatment group contained a DMSO 
control comparable to the DMSO content of the highest drug concentration used for that 
treatment group (i.e. 1% v/v for the Osimertinib group, and Sotorasib groups, and 1.5% v/v for 
the Crizotinib group). Plates were drugged for 4 h at 37 ℃ in 5% CO2 in air to study the 
immediate impacts of each drug on the MAPK pathway.  
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Figure 7: Drug concentrations used to generate DTP cell populations. This was based on 
concentrations determined via proliferation assays analysed prior. Image created using 
BioRender.com. Original work, Davis 2021. 
 
2.4.3 Protein Extraction: 
In preparation for protein extraction, fresh 1x RIPA buffer was prepared from 500 µL 2x RIPA 
(see appendix II), before being diluted to 1x concentration with 400 µL MilliQ water and 100 
µL protease/phosphatase inhibitors (PPIs; Roche) to prevent protein degradation and 
alterations such as dephosphorylation. Growth medium was then removed from each 10 cm 
dish and the cells were washed twice with 2 mL of ice-cold PBS. PBS was removed with a 10 
mL pipette, followed by a 1 ml pipette to ensure complete removal of PBS. Plates were 
processed immediately or frozen at -80℃ until required. 100 µL of 1x RIPA buffer with PPIs 
was added to each dish and the back of a 1 mL pipette tip was used to scrape the dish. Cell 
lysate was then transferred to a pre-cooled 1.5 mL microfuge tube and incubated on ice for 30 
m. Following this, the cell lysate was centrifuged at 13,000 rpm for 15 min, resulting in 
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supernatant containing protein. The supernatant was then transferred into a fresh pre-cooled 
1.5 mL microfuge tube and used for BCA assay analysis or frozen at -80 ℃.  
 
2.4.4 BCA Assay:  
To generate a standard curve from which to determine the concentration of protein samples, 
serial dilutions of BSA Standards were prepared. This was achieved by adding 20 µL of 1x 
RIPA buffer to 7x 1.5 mL microfuge tubes. 20 µL of Pierce BSA reagent (ThermoFisher 
Scientific) at a concentration of 2000 µg/mL was added at a concentration of 1:1 to the 1x 
RIPA buffer in the first 1.5 mL microfuge tube and was used to perform a serial dilution series. 
20 µL of Pierce BSA reagent was then added to an eighth 1.5 mL microfuge tube at a 
concentration of 2000 µg/ml. 
 
Protein samples were then prepared by diluting 1:10 in 1x RIPA buffer. 5 µL of each sample, 
as well as the protein standards were loaded in duplicate into a 96-well plate. Working reagent, 
consisting of 1-part CuSO4 and 50 parts bicinchoninic acid (BCA) was made according to the 
manufacturers protocol (ThermoFisher Scientific). 100 µL of working reagent was then added 
to each well. The 96 well plate was then covered in tinfoil to prevent drying and incubated at 
35℃ for 30 min. Plates were read by a Victor fluorimeter set at 485 nm excitation/535 nm 
emission.  
 
Final protein concentrations were determined via generating a standard curve from the protein 
standard serial dilution. An r2 value of 0.98 or higher was considered acceptable The linear 
equation of the standard curve was then used to determine the protein concentration of the 
samples.  
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2.4.5 Protein Preparation:  
Once protein concentration had been determined, 50 micrograms of protein was prepared in 
Laemmli buffer (see Appendix II). For a 1x protein solution, the following was added (Table 
4). Following protein preparation, samples were heated to 95℃ for 5 min to denature proteins 
and remove protein secondary structure to ensure that the protein samples ran based on size 
alone.  
Table 4: Reagents Required for Protein Preparation 
Reagent: Per 1x Protein Solution: Per 2.5x Protein Solution for 
Loading: 
4X Laemmli Buffer: 5 µL 12.5 µL 
5% v/v Beta-mercaptoethanol  0.5 µL 1.5 µL 
Protein 50 ug 125 ng 
1x RIPA Buffer Up to 15 µL Up to 37.5 µL 
 
2.4.6 Polyacrylamide Gel Electrophoresis: 
Prior to use, 4-20% Mini-PROTEAN TGX Precast 12-well protein gels (Bio-Rad) were 
washed to remove unpolymerized polyacrylamide. 25 µL of sample, alongside 10 µL precision 
plus dual colour standards (Bio-Rad) were loaded into the gels. Electrophoresis buffer was 
added to the cassette (see Appendix II) and proteins were then separated at 100 V until the dye 
front reached the bottom of the gel (around 90 min).  
 
2.4.7 Transfer: 
Nitrocellulose membranes, blotting paper, and sponges were all soaked in pre-cooled transfer 




Figure 8: Cassette loading for protein transfer. Image created using BioRender.com. 
Original work, Davis 2021. 
 
Air bubbles were removed from before being loaded into the transfer rig. The transfer rig was 
then filled with transfer buffer (see Appendix II) and run at 30 V overnight to transfer the 
protein onto the nitrocellulose membrane. 
 
2.4.8 Blocking:  
Once transfer was completed, the membrane was washed with 10 mL TBS-Tween (0.1% v/v) 
(see Appendix II. Blocking then commenced by incubating the membrane in 10 mL of blocking 
buffer (see Appendix II) with gentle agitation for 1 h.  
 
2.4.9  Addition of Primary and Secondary Antibodies: 
Prior to the addition of antibodies, the membrane was washed 5 times for 5 min in TBS-Tween 
(0.1% v/v) with gentle agitation. Following this, the membrane was incubated in primary 
antibody (summarised in Table 5; either rabbit anti-ERK (anti-p44/42 MAPK), rabbit anti-
pERK (anti phospho-p44/42 MAPK)), or for housekeeping, rabbit anti-histone H3 at a dilution 
of 1 in 5000 overnight at 4℃ in 10 mL blocking buffer and with gentle agitation. 
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Table 5: Antibodies used in Western Blotting. 
Antibody Catalogue 
Number 
Company  Animal of 
Origin 
Dilution 
Anti-p44/42 MAPK (ERK) 9102 Cell 
Signalling 
Technology 











Rabbit 1 in 5000 
IRDye 680RD Goat anti-Rabbit 
IgG Secondary Antibody 
926-68071 LI-COR 
 
Goat 1 in 25000 
 
 A second wash phase was then performed, consisting of four 5-min washes in TBS-tween 
(0.1% v/v) with gentle agitation to remove non-specific staining. The membrane was then 
incubated in secondary antibody (see Table 6 above) at a dilution of 1 in 25000 in 10 mL 
blocking buffer under gentle agitation. The third and final wash phase then began with four 5-
min washes in TBS-Tween (0.1% v/v) with gentle agitation. This was followed by two 5-min 
washes in TBS alone under agitation. The addition of secondary antibody and subsequent wash 
steps were all performed in the dark.  
 
2.4.10 Membrane Imaging and Analysis of Western Blotting: 
Membranes were imaged using the LI-COR Odyssey CLx imaging system and were analysed 
using Image Studio Lite version 5.2.5.  
 
2.5 Crystal Violet Staining and Imaging:  
Duplicate 10 cm dishes for each treatment group in each cell line were seeded and drugged as 
described previously (sections 2.4.1 and 2,4,2). Following 72-h drug treatment, one set of 
treated 10 cm dishes was stained with crystal violet by removing drug and growth medium, 
adding a homogenous layer of stain. Following 10-mins of staining, stain was removed, and 
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cells were washed twice with distilled water. Simultaneously, the other set of treated dishes 
had growth medium and drug removed. Two washes with fresh medium were then performed 
to remove and remove any remaining drug. The dishes were then incubated for a further 96 h 
before being stained as above. Once all dishes had dried, they were imaged. Imaging of plates 
at 1x magnification was achieved via Epi white imaging on a Gel Doc XR+ from BioRad. 
Magnified images were taken using the 4x and 20x lenses on an EVOS XL Core Imaging 
System from ThermoFisher Scientific. 
2.6 Real-Time Quantitative Polymerase Chain Reaction (RT-
qPCR): 
2.6.1 RNA Extraction and Determination of RNA Quality:  
Following 72-h drug treatment, 10 cm plates were stored on ice while medium was removed. 
Each dish was washed twice with 2 mL PBS and frozen at -80°C for storage and to aid cell 
lysis. RNA extraction was performed on ice using the PureLink RNA Mini Kit (ThermoFisher) 
according to the manufacturers protocol with the following exception: columns were 
centrifuged for 30 s instead of 15 s to allow the rotor sufficient time to reach the centrifugation 
speed of 12,000 rpm during each step. RNA was eluted in 30 µL RNase-free H2O before being 
used to generate cDNA or was stored at -80℃.  
 
RNA concentration and overall quality was then determined using a NanoPhotometer N60 
nanodrop spectrophotometer (Implen Inc) using the same RNase-free H2O from the elution 
step used of the RNA extraction to blank the spectrophotometer (from the Ambion RNA Mini 
Kit). RNA quality was determined via evaluation of 260 nm/280 nm and 260 nm/230 nm 
absorbance ratios and absorbance graph provided by the spectrophotometer.  
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2.6.2 cDNA Synthesis: 
For cDNA synthesis, 1000 ng of RNA was prepared in a total volume of 16 µL using RNase 
and DNase free H2O. Following this, 4 µL of qScript cDNA Supermix (Quantabio) was added 
and cDNA was synthesized in a thermal cycler according with the following parameters:  
Table 6: cDNA Synthesis protocol for Thermal Cycler: 
Step Temperature Hold 
(hh:mm:ss) 
Step 1 25℃ 0:05:00 
Step 2 42℃ 0:30:00 
Step 3 85℃ 0:05:00  
Step 4 4℃ Indefinitely 
 
cDNA was diluted to a concentration of 10ng/uL in 80 µL RNase and DNase free H2O and the 
quality of cDNA was determined via Implen Inc NanoPhotometer N60 nanodrop 
spectrophotometer using RNase and DNase free H2O to blank the spectrophotometer. cDNA 
was stored at -20 ℃ until required or processed immediately.  
 
2.6.3 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR): 
RT-qPCR was carried out using the TB Green Premix Ex Taq II (Tli RNase H Plus) master 
mix kit (Takara). Primer master mixes for RT-qPCR were prepared on ice for each gene 
according to Table 7 and multiplied depending on the number of PCR reactions performed per 




Table 7: RT-qPCR Primer Master Mix Components for One RT-qPCR Reaction: 
Reagent Volume 
(µL) 
2X Sybr Mix TB Green Premix Ex Taq II (Tli RNase H 
Plus)  
5.00 
10 µM Forward Primer 0.40 
10 µM Reverse Primer 0.40 
Nuclease-free H2O 3.16 
ROX 0.04 
Total Volume 9.00 
 
The primer master mix was then thoroughly vortexed and 9 µL or primer master mix was added 
to its corresponding well on a 96-well plate. 1 µL of cDNA template was then added and the 
RT-qPCR reaction protocol was performed QuantStudio’s Flex 7 qPCR machine according to 
the protocol found in Table 8.  
 
Table 8: RT-qPCR Reaction Protocol 
Stage Temperature (℃) Hold (hh:mm:ss) Number of Cycles 
Hold Stage 95 0:00:30 1 
 95 0:00:05  
 60 0:00:30  
 95 0:00:15  
Melt Curve Stage 60 0:01:00 1 
 95 0:00:15  
 
2.6.4 RT-qPCR Analysis:  
Following RT-qPCR, raw cycle threshold (CT) values were normalised to the housekeeping 
gene UBC and were expressed relative to the DMSO control following the 2∆∆CT method111. 
Results were the graphed using GraphPad Prism 9 for MacOS (v. 9.0.1).  
40 PCR Stage  
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3 Results:  
3.1 Treatment with Targeted Therapies Results in the Survival of 
a Persistent Tolerant Population  
Previous studies have shown that PC9 cells are able to generate DTPs at high concentrations 
of mutation specific drug8, 49. We performed SYBR proliferation assays by treating with 
osimertinib, crizotinib and sotorasib on PC9, H3122, H358 and LL2 cells respectively over a 
period of 72 h to determine the concentrations of targeted drug required to generate DTPs in 
each cell line (Figures 9 and 10). When normalised to untreated (DMSO) controls, we found a 
small pool of cells (around 10%) were able to survive treatment even at very high 
concentrations of up to 50 µM of mutation specific drug in PC9, H3122 and H358 cell lines 












Figure 9: Proliferation assays showing the growth of the indicated cell lines following treatment with 
increasing doses of the mutation specific drugs (A) osimertinib, (B) crizotinib and (C) sotorasib. N=3 
for each experiment. Error bars represent standard deviations from the mean. 
 
 








































































LL2 cells failed to respond to sotorasib treatment, with over 50% cells remaining despite 
treatment with up to 10 µM sotorasib when normalised to an untreated (DMSO) control (Figure 
10). This will be discussed further in section 4.1 of the Discussion. LL2 cells were not used 
further in the present study.  
 
Figure 10: Proliferation assay displaying the percent cells in LL2 cells following treatment with 
sotorasib relative to LL2 cells treated with DMSO as a control. N=1. Error bars represent standard 
deviations from the mean.  
 
Proliferation assays plotted on a log10 x-axis may be found in Supplementary Figure 1. From 
these results concentrations of 2 µM, 5 µM, and 10 µM Osimertinib, 5 µM, 10 µM, and 15 µM 
Crizotinib, and 1 µM 5 µM, and 10 µM Sotorasib were selected to generate DTPs in PC9, 
H3122 and H358 cells respectively for further experiments.  
 
3.2 Western Blotting Confirms MAPK Pathway Inhibition 
Following Treatment with Osimertinib in PC9 Cells:   
In order to confirm that the mechanism of action of each mutation specific drug at the 
concentrations present in our study was by inhibiting the MAPK pathway, we performed 
western blotting for the MAPK downstream effector protein ERK, and its active form pERK 
(Figure 11).  
 





















Due to time restraints following COVID-19 lockdown, western blotting for ERK and pERK 
was only able to be performed in PC9 cells. Following 4-h treatment with 2 µM, 5 µM, and 10 
µM osimertinib, we found that the levels of ERK protein remained stable, while a marked 
reduction in ERK phosphorylation was observed in PC9 cells (Figure 11). Bands representing 
both p44 and p42 subunits were observed for both ERK and pERK. Histone H3 was used as a 
loading control. Full blots can be found in Supplementary Figures 2 and 3.  
 
Figure 11: Western blotting for the downstream MAPK effector ERK and its active form pERK in PC9 
cells following treatment with either DMSO (control), 2 µM osimertinib, 5 µM Osimertinib or 10 µM 
Osimertinib. Drug treatments were performed over a 4-h period. Following treatment a reduction in 
ERK phosphorylation was observed. Histone H3 was used as a loading control. N=1. 
3.3 DTP Morphology Following 72-Hour Drug Treatment:  
Using the dose ranges obtained prior (section 3.1), DTPs were generated over a period of 72 h 
via treatment with mutation-specific drugs. Cells were then imaged via digital inverted bright-
field microscopy and representative images are shown below in Figure 12. Following 
treatment, a reduction in cell density was observed in each of the treated dishes, reflecting the 
large amount of cell death occurring as a result of treatment. DMSO treated controls appeared 
to be very confluent at the 72 hour time point and cell growth did not appear to be inhibited by 
treatment with DMSO.  
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Morphologically, DTPs generated in each cell line looked similar to their parental cell 
population when treated with relatively lower doses of mutation specific drug (2 µM 
osimertinib, 5 µM crizotinib and, 1 µM sotorasib for PC9 cells shown in A, H3122 cells shown 
in B, and H358 cells shown in C respectively). However at higher doses the appearance of cells 
began to diverge away from their parental counterparts. This was particularly noticeable in PC9 
cells (panel A) following 10 µM osimertinib treatment, and was also clearly visible at higher 
concentrations in panels B and C for H3122 and H358 cells respectively with some cells 
appearing granular (examples indicated by arrows). This will be discussed at length in the 
Discussion section (section 4).  
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Figure 12: Brightfield microscopy visualization of DTPs following treatment with mutation specific drug for 72 h. PC9, H3122 and H358 cells were treated 
the mutation-specific drugs (or DMSO control) as indicated, and growth and morphological characteristics assessed by brightfield microscopy. Overall, a 
reduction in cell density was observed for each cell line. Granular cells were observed at higher concentrations and are indicated with arrows. N=3, 
representative images shown. Scale bar = 1 mm
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3.4 Crystal Violet Staining Reveals Re-Growth of Lung 
Adenocarcinoma DTPs Following Drug Washout:  
To investigate the viability of cells that survive treatment, crystal violet staining was performed 
on each cell line following 72-h treatment with mutation-specific drug (Figure 13, panels A, 
C, E), and cells following 72-h treatment with mutation-specific drug with a 96-h drug washout 
period, in which drug was removed and cells were cultured in fresh growth medium (Figure 13 
panels B, D, F). Cells were then imaged at 1x, 4,x, and 20x, magnifications. Following drug 
washout, each cell line experienced cell re-growth, with clear colonies forming even following 

















































72-Hours Treatment  
72-Hours Treatment  
+ 96-Hours Washout 
DMSO 1 µM Osi 5 µM Osi 10 µM Osi DMSO 1 µM Osi 5 µM Osi 10 µM Osi 
DMSO DMSO 5 µM Cri 10 µM Cri 15 µM Cri 
 
DMSO 1 µM Sot 5 µM Sot 10 µM Sot DMSO 1 µM Sot 5 µM Sot 10 µM Sot 
 
Figure 13: Crystal violet staining of PC9, H3122 and H358 (panels A, B), H3122 cells (panels C, D) and H358 cells 
(panels E, F) Following either 72-h drug treatment (left column) or 72-h drug treatment preceding 96-h drug washout 
(right column). PC9 cells were treated with 2 µM, 5 µM, and 10 µM osimertinib (panels A,B), H3122 cells were 
treated with 5 µM, 10 µM, and 15 µM crizotinib (panel C, D), and H358 cells were treated with 1 µM, 5 µM, and 10 
µM sotorasib (panel E, F). Each experiment contained an untreated DMSO control shown on the left in each panel. 
Each experiment was imaged at 1x magnification (top of each panel), 4x (middle of each panel, scale bar = 1 mm), 
or 20x (bottom of each panel, scale bar = 100 µm). N=1. 
A B 
D 
5 µM Cri 10 µM Cri 15 µM Cri C 
F E 
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3.5 HPRT1 is Not a Stable Housekeeper for PC9 and H358 Cell 
DTPs: 
RT-qPCR was performed on each cell line following 72-h treatment with mutation specific 
drugs to determine the expression of stem cell and lung progenitor cell genes of interest. 
Prior to stem and progenitor cell expression analysis, we found that the common housekeeping 
gene, HPRT1, was downregulated in 1.7-fold in PC9 cells in response to treatment with 
osimertinib, and by 3-fold in sotorasib treated H358 cells compared to DMSO controls (Figure 
14). H3122 cells treated with crizotinib did not show a significant change in HPRT1 gene 
expression in response to crizotinib treatment. Based on these results, HPRT1 was not used 
further as a housekeeping gene for RT-qPCR in the present study. Expression from our second 
housekeeping gene, UBC, remained consistent, allowing us to continue with RT-qPCR analysis 
of stem and progenitor cell markers in DTPs. This will be discussed further in section 4.4.  
 
 
Figure 14: RT-qPCR for HPRT1 in DTPs Generated from PC9, H3122 and H358 Cell Lines Treated 
with 2 µM Osimertinib, 5 µM Crizotinib and 1 µM Sotorasib Respectively. Each experiment was 
performed 3 times (n=3). Error bars represent standard deviations from the mean. ns=not significant, 


































3.6 Expression of the Stem Cell Factors OCT3/4, NANOG and 
SOX2 in DTPs: 
Previous literature has identified the pluripotent nature of DTPs over extended time intervals 
8. We investigated the expression of the stem cell factors OCT3/4, NANOG and SOX296, 98 in 
DTPs over a short treatment period of 72 h relative to DMSO treated controls (Figure 15). For 
reasons discussed in the Discussion section (section 4), we decided to focus on the lower doses 
of targeted therapy for RT-qPCR analysis. Treatment with higher concentrations of mutation 
specific drug can be found in Supplementary Figures 4-6. 
 
In PC9 cells (panel A), the expression of OCT3/4, NANOG and SOX2 was upregulated when 
treated with 2 µM osimertinib, with OCT3/4 expression upregulated 4-fold, NANOG 
expression upregulated 2.5-fold and SOX2 expression upregulated 2-fold when treated with 
2µM osimertinib. H3122 cells treated with 5 µM crizotinib (panel B) did not change their 
OCT3/4 expression in the treated vs untreated control groups, while NANOG was 
downregulated 2.5-fold when treated with 5 µM crizotinib. SOX2 was upregulated 13-fold 
following treatment compared to the DMSO control. Similar to stem cell factor expression in 
PC9 cells, H358 cells saw a dramatic upregulation in stem cell OCT3/4 and NANOG expression 
(panel C). 1 µM sotorasib treated H358 cells experienced a 6-fold upregulation in OCT3/4, and 
a 5-fold upregulation in NANOG. Interestingly, SOX2 expression was downregulated 4-fold 





Figure 15: Expression of stem cell factors OCT3/4, NANOG and SOX2 in DTPs determined by RT-
qPCR analysis following 72 hour indicated mutation specific drug treatment in (A) PC9 (B) H3122 and 
(C) H358. Each experiment was performed 3 times (n=3). Error bars represent standard deviations 





























































































3.7 Expression of AT2 Lineage Factors in DTPs in LUAD:  
A recent study utilizing single-cell RNA sequencing (scRNA-seq) of patient biopsies has 
suggested that DTPs may revert back to a primitive state of development, mimicking alveolar 
type-2 (AT2) cells, an alveolar cell with stem like progenitor properties. We investigated the 
AT2 cell markers FOXA2, NKX2-1, SFTPB, SFTPC and SFTPD in in vivo DTPs generated 
over a period of 72 h via RT-qPCR (Figure 16). Treatment with high concentrations of mutation 
specific drug can be found in Supplementary Figures 4-6. 
 
Unexpectedly, PC9 cells did not to express FOXA2 or NKX2-1, with such low expression as to 
prevent cDNA reaching cycle threshold in both DMSO control and cells treated with 2 µM of 
osimertinib (Supplementary Tables 1-6). The surfactant genes SFTPB, SFTPC, and SFTPD 
were upregulated 6-fold, 5-fold, and 2.5-fold respectively in PC9 cells treated with 2 µM 
osimertinib compared to the DMSO control (panel A). 
 
Interestingly, FOXA2 expression in H3122 cells was downregulated 6-fold in response to 5 µM 
crizotinib treatment, while NKX2-1 expression was upregulated by 7-fold. The surfactant gene 
STFPB decreased expression by 5-fold in response to treatment, while STFPC, and STFPD 
expression was upregulated 2-fold and 5-fold respectively when treated with 5 µM crizotinib.  
 
In H358 cells, FOXA2 expression was downregulated 2.5-fold following treatment with 1 µM 
sotorasib, while NKX2-1 showed a slight upregulation of 1.3-fold following treatment. Each of 
the surfactant genes, SFTPB, SFTPC, and SFTPD, were upregulated following treatment, with 
7-fold, 5-fold and 9-fold increases in expression occurring for SFTPB, SFTPC, and SFTPD 




Figure 16: Expression of AT2 lineage associated markers analysed by RT-qPCR in(A) PC9 (B) H3122 
and (C) H358 cells following treatment with indicated drugs. Each experiment was performed 3 times 
(n=3). Error bars represent standard deviations from the mean.  n.d. = not detected. Ns=not significant, 





















































































































3.8 Identification of AQP4 as a Potential Cell Surface Marker for 
DTPs in Lung Adenocarcinomas: 
To determine whether DTPs are pre-existing or are induced by drug treatment, genes able to 
be separated via florescence activated cell sorting (FACS) are required. We identified the genes 
MRAS and AQP4 as potential candidates for FACS isolation for DTPs67, 112 and performed RT-
qPCR on each gene to determine their expression in DTPs, results of this analysis are found 
below in Figure 17. Treatment with high concentrations of mutation specific drug can be found 
in Supplementary Figures 4-6. 
 
Following treatment with 2 µM of osimertinib (panel A), PC9 cells did not show a statistically 
significant change in MRAS expression. MRAS expression was downregulated by 2-fold in 
H3122 cells treated with 5 µM crizotinib, while H358 cells treated with 1 µM sotorasib also 
did not show any statistically significant change in MRAS expression.  
 
AQP4 expression was upregulated in each cell line following treatment, with PC9 cells treated 
with 2 µM of osimertinib exhibiting a 5-fold upregulation in AQP4, while H3122 cells treated 
5 µM crizotinib showed an 8-fold upregulation in AQP4 and H358 cells treated with 1 µM 







Figure 17: Expression of MRAS and AQP4 analysed by RT-qPCR in (A) PC9 (B) H3122 and (C) H358 
cells following treatment with indicated drugs. Each experiment was performed 3 times (n=3). Error 
bars represent standard deviations from the mean. ns=not significant, *=P ≤ 0.05, **=P ≤ 0.01, ***=P 















































































Drug tolerant persisters (DTPs) are cells that use non-genetic mechanisms to enter a reversible 
state of dormancy to weather treatment. Previous literature has identified the role of stem cell 
and lung progenitor genes in drug tolerance over extended timepoints8, 67. The mechanism that 
underpins this response is currently unknown and it is unclear whether drug tolerance emerges 
prior to treatment or is induced upon drug treatment. We aimed to determine the role of stem 
and lung progenitor cell factors in DTPs emerging over early timepoints, and to establish 
whether drug tolerance occurs prior to treatment or occurs in response to treatment.  
 
4.1 Drug Tolerant Persisters were Generated at High Doses of 
Molecularly Targeted Drug in Three Lung Adenocarcinoma 
Lines:  
The first aim of this study was to determine the concentration of targeted therapy require to 
generate a pool of DTPs in each cell line. We achieved this using proliferation assays (section 
3.1), a technique commonly used to find the concentration of targeted therapy required to 
generate DTPs8, 11, 12, 113. In PC9, H3122 and H358 cell lines we found a dramatic reduction in 
cell number in a dose-dependent manner when treated. Significantly, a small pool of around 
10% or less of the control untreated population of cells persisted despite increasing 
concentrations of targeted therapeutic. This population is analogous to those found in previous 
literature, in which a persistent cell population of around 10% or less remained despite ongoing 
treatment8, 11, 12, 113. Surprisingly, this population persisted despite concentrations of up to 50 
µM of each targeted agent in the present study.  
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Given the similarity in assay methods and findings with previous literature, evidence suggests 
that that we have isolated the population defined by previous literature as “drug tolerant 
persisters8” in PC9, H3122 and H358 cells treated with their respective molecularly targeted 
drug over the shortened timepoint of 72 h. Based on this finding, we used the equitoxic 
concentrations of mutation specific drug required to generate DTPs in each cell line to inform 
our decision on generating DTPs for further experiments found in the present study. Detailed 
information regarding concentrations of mutations specific drug is found in the Methods 
section (section 2.4.2).  
 
Unexpectedly, the KRAS mutant and murine derived LL2 cell line failed to respond to 
sotorasib treatment, with the total cell number failing to reduce more than 50% of the untreated 
population despite increasingly high concentrations of sotorasib (Figure 10). While LL2 cells 
carry the target of sotorasib inhibition, KRASG12C, LL2 cells also harbour an NRASQ61H 
mutation114. Interestingly, research on the LL2-derived 3LL cell line found that the NRASQ61H 
mutation facilitated bypass of KRASG12C inhibition when treated with the KRASG12C inhibitor 
ARS-1620115. This resulted in KRASG12C inhibition alone having little effect on cell 
viability115. Furthermore CRIPSR-Cas knockout of NRAS promoted a strong sensitivity to 
ARS-1620 and KRASG12C inhibition, resulting in both a strong reduction in downstream 
MAPK signalling and a loss of cell viability115.This finding is reflected in our data (see Figure 
10) and suggests that the cause of LL2’s failure to respond to sotorasib treatment is likely due 
to NRASQ61H facilitating bypass of KRASG12C inhibition by sotorasib in LL2 cells, resulting in 
sustained cell viability despite high concentrations of sotorasib. While further investigation is 
needed to confirm this, KRASG12C inhibition bypass via NRASQ61H seems a likely explanation 
as to why LL2 cells failed to respond to sotorasib. 
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To conclude, we were able to generate DTPs over the short period of 72 h and determined 
equitoxic concentrations of molecularly targeted therapy in PC9, H3122 and H358 cells in 
order to further investigate drug tolerance in these cell lines.  
 
4.2 Osimertinib Reduces PC9 Viability via MAPK Inhibition: 
It is well established in current literature that the mechanism of action for the targeted therapies 
used throughout this thesis, osimertinib, crizotinib, and sotorasib, is via inhibition of the 
upstream nodes of the MAPK pathway (see Figure 3)34, 116, 117. This prevents the 
phosphorylation-dependent activation of the effector MAPK signalling protein, ERK34, 116, 117. 
In order to confirm this mechanism of action for each targeted therapy at the concentrations 
used in the present study, western blotting was performed for phosphorylated ERK (pERK) 
(Figure 11). Unfortunately due to COVID-19, western blotting for pERK was only able to be 
performed on PC9 samples.  
 
Following western blotting, we found that PC9 cells treated with 2, 5, or 10 µM osimertinib 
lost phosphorylation of ERK, suggesting that osimertinib was inhibiting the MAPK pathway 
at the concentrations used in the present study in PC9 cells. This suggests that the bulk of cell 
death observed in the prior proliferation assays (section 3.1) was the result of MAPK inhibition, 
causing cell death in the MAPK oncogene addicted and dependant PC9 cells118. While we were 
not able to repeat this experiment in H3122 and H358 cell lines, given previous and well-
established literature outlining the mechanisms of action of these pathways116, 117, we would 
expect that the findings would be identical to those observed in PC9 cells. 
 
As we were aiming to assess the direct impacts of osimertinib on MAPK inhibition in this 
experiment, a drug treatment period of 4-h was chosen. This allowed us to assess the direct 
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inhibitory action of osimertinib at the concentrations used, instead of providing time for the 
development of secondary cytotoxic effects of MAPK inhibition, such as alterations to cell 
signaling and metabolism119-121. Secondly, this prevents time for bypass pathway activation, 
resulting from the activation of secondary pathways that restart the MAPK pathway122. 
Collectively, this results in a return of pERK activation over extended periods of time, a 
phenomenon commonly observed in previous literature123. To avoid this, we chose to perform 
western blotting following 4-h of treatment with osimertinib in PC9 cells to be able to observe 
MAPK pathway inhibition.  
 
However, the decision to perform drug treatments over a 4-h period for western botting does 
introduce limitations to this experiment. Because we generated DTPs over a 72 h period, we 
cannot be sure that MAPK inhibition remains intact in DTPs, meaning that we can only claim 
that MAPK inhibition preceded the formation of DTPs and inhibition may not be present in the 
DTPs themselves. While this would seem unlikely given the extreme drug-tolerant phenotype 
required to persist, further experiments are required to confirm this.  
 
In summary, we found that MAPK signaling was indeed inhibited in PC9 cells following 4-
hours of treatment with osimertinib at the concentrations used in the present study, thus 
supporting our hypothesis. Future experiments should focus on repeating this experiment in 
H3122 and H358 cell lines prior to DTP generation to confirm MAPK pathway inhibition in 
these cell lines and should perform western blots on proteins extracted at multiple timepoints 
in all three cell lines to determine the phosphorylation status of ERK and how this may change 
over time.  
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4.3 Morphological Differences in DTPs Generated at Different 
Drug Concentrations 
To examine the cell morphology of PC9, H3122 and H358 DTPs, brightfield images were 
taken of cell treated with targeted therapies in each cell line (Figure 12). This resulted in several 
interesting findings. Expectedly, treatment with each targeted agent over 72 h resulted in a 
significant decrease in cell density in each cell line. This result, although expected8, 11, 12, 113, 
was vital, as it shows that a small pool of cells are able to persist despite treatment over 72 h.  
 
Interestingly, it initially appeared that a larger pool of cells survived treatment than originally 
expected. This was surprising given the relative number of cells that survived treatment in the 
previous proliferation assay experiments with the same concentrations of drug and the 
surviving pool of cells following treatment found in previous literature8. This may be explained 
however with the higher initial seeding density used, especially for PC9 and H3122 cell lines, 
which were plated at a density of 500,000 cells/mL. This resulted in a similar overall surviving 
percent of cells compared to each DMSO control between the proliferation assays, previous 
literature and brightfield images. This was reflected in the DMSO control for each experiment 
which was very confluent, particularly for the PC9 and H3122 treatment groups which were 
plated at a higher seeding density. While cell confluency will be discussed further in this 
discussion in section 4.7, it is important to note that this may have played a role in our findings, 
in particular the ability to compare PC9 and H3122 DTPs with H358 DTPs, and additionally 
in the normalisation of RT-qPCR CT values to the highly confluent DMSO controls.  
 
Previous literature has consistently shown that DTPs appear to be morphologically similar to 
their untreated counterparts8. We found that at the doses of 2 µM osimertinib in PC9 cells, 5 
µM crizotinib in H3122 cells and 1 µM sotorasib in H358 cell lines, cells remained 
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morphologically similar to their untreated cell counterparts. However, at higher doses of each 
targeted therapeutic, the cell morphology appeared to change significantly, becoming 
increasingly granular and dark visually. This was particularly noticeable in PC9 cells treated 
with 10 µM osimertinib as indicated by the arrow in Figure 12, but was also seen in each of 
the other cells lines particularly at their highest concentration of targeted therapy. We 
hypothesized that this was due to cell becoming increasingly senescent in response to 
treatment. This finding is supported by previous literature which found that co-treatment of 
PC9 cells with high concentrations of the EFGR inhibitor gefitinib and resveratrol resulted in 
increasingly granular cells with a morphology matching these observed in the present study124. 
The authors of this study suggest that the cause of this granularity is through cellular senescence 
in PC9 cells in response to treatment124. Given the morphology of cells observed in this study 
is very similar to our own, it would seem likely that the cells of the present study are exhibiting 
the characteristics of senescence at high concentrations of drug. It is unknown whether this 
response was due to the direct inhibition of the MAPK pathway by targeted therapy, if this is 
a part of the DTP response, or if this is in fact the result of off target effects given the relatively 
high doses of targeted agent used. 
 
To explore this further, we performed crystal violet assays to determine whether cells in the 
high dose treatment groups for each cell line remained viable, despite their changes to 
morphology (Figure 13). To do this we compared cells drugged for 72 h with cells drugged for 
72 h followed by drug wash out and incubation in fresh media for a further 96 h. In each cell 
line we found cell re-growth after drug washout. This suggests that despite the changes to 




Future experiments should measure the abundance of the senescence associated marker β-
galactosidase in DTPs. This assay is commonly used to measure cell senescence 124, 125. It 
would be interesting to determine whether it is DTPs that are becoming senescent, if this is 
another subpopulation of lung cancer cells, or if these cells were the canonical “DTPs” that 
have since non-genetically adapted further to treatment. This would be especially interesting 
to determine given the RT-qPCR expression of cells at these higher doses (supplementary 
Figures 4-6) which was largely dissimilar to DTPs generated previously literature8 and DTPs 
generated at lower concentrations of drug.  
 
This may suggest that at such high concentrations, DTPs form subpopulations that co-exist to 
survive treatment. Given recent findings that suggest the presence of multiple subpopulations 
of DTPs with differing cycling status and metabolic profiles113. This could also explain the 
differences in gene expression found at the different drug concentrations, a topic that will be 
discussed further on in this chapter.  
 
Given this change in morphology and RT-qPCR findings, we made the decision to focus on 
the relatively lower doses of 2 µM osimertinib, 5 µM crizotinib and 1 µM sotorasib for 
interpretation in order to avoid the possible confounding effects of varied subpopulations of 
distinct DTPs in gene expression. Given the lack of understanding in this area, further research 
on why both cell morphology and gene expression changes at these high concentrations is 




4.4 DTPs Upregulate Pluripotency Markers Following 72-h Drug 
Treatment.  
The idea of cancer cells hijack the processes that underly pluripotency in stem cells to become 
not only malignant, but adaptable and thus difficult to treat, has been at the forefront of cancer 
biology for decades126, 127. It therefore comes as no surprise that accumulating evidence is 
pointing to a significant involvement of pluripotency cell factors in the emergence of DTPs8, 
51, 66, 73. Previously, Sharma and colleagues uncovered the role of global epigenetic alterations 
in changes to pluripotency factors leading to drug tolerance8. Since this discovery, pluripotency 
factors have been consistently implicated in the emergence of drug tolerance 51, 66, 73. However, 
the majority of this research has focussed either on PC9 LUAD cells8, 66, or other cancer types 
altogether13, 51, and thus the role of pluripotency factors in LUAD DTPs remains unclear. 
Additionally, previous research has focussed on the relatively late timepoints of weeks to 
months8, resulting in limited knowledge on DTPs emerging at earlier timepoints following drug 
treatment. We aimed to investigate the expression of pluripotency factors in LUAD DTPs in a 
panel of LUAD cell lines, including PC9, H3122 and H358 cell lines, treated with targeted 
therapeutics over the relatively sort timepoints of 72 h. To investigate this, we performed RT-
qPCR analysis in OCT3/4, NANOG and SOX2 (section 3.6).  
 
Results from our initial analysis was initially confusing, with no discernible pattern visible 
following analysis. Intrigued by this, we found that the expression of one of our housekeeping 
genes, hypoxanthine-guanine phosphoribosyl-transferase 1 (HPRT1) was consistently 
downregulated in a dose dependant manner in response to osimertinib and sotorasib treatment 
in PC9 and H358 cells respectively (Figure 14). Importantly, variation in HPRT1 expression 
could not be put down to fluctuations in cDNA quantity alone, as the volume of mRNA 
required for cDNA synthesis was modulated to produce 1000 ng of cDNA (see section 2.6.2) 
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and the quantity of cDNA was regularly checked via spectrophotometry. Any variations in 
cDNA quantity were accurately reflected in the second housekeeping gene, ubiquitin C (UBC) 
cycle threshold (CT) values.  
 
HPRT1 is a protein coding gene that catalyses conversion of 5'-phosphoribosyl-l-
pyrophosphate (PRPP) and the purine bases to inosine monophosphate and guanosine 
monophosphate in the purine salvage pathway128-130. It is well known that HPRT1 is 
upregulated in malignant tissues compared to normal tissues in many cancers131, 132. This is 
likely due to the requirement of rapidly proliferating cells for purine nucleotides, leading to an 
upregulation of HPRT1 to meet the excessive demand133, 134. Therefore it would seem likely 
that the cause of HPRT1 downregulation in the present study is due to the selection of a DTP 
population that is known to cycle slowly8, 75, removing the requirement for rapid purine 
nucleotide generation and thus downregulating HPRT1, reflecting our findings. Because of 
this, we would suggest that future DTP research does not use HPRT1 as a housekeeping gene 
for RT-qPCR.  
 
We were able to continue with our RT-qPCR experiments due to the use of the stable 
housekeeping gene UBC. We found that UBC expression that did not change despite drug 
treatment. This is consistent with literature that suggests that UBC is a stable housekeeping 
gene135. As such, RT-qPCR analysis was performed on PC9, H3122, and H358 cell lines for 
OCT3/4, NANOG, and SOX2 (see figure 15).  
 
Interestingly, OCT3/4 and NANOG were significantly upregulated in DTPs compared to 
untreated controls in both PC9 and H358 cell lines. Both OCT3/4 and NANOG regulate 
stemness and pluripotency96, 98, and this finding suggests that OCT3/4 and NANOG are 
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contributing to the drug tolerant phenotype present in PC9 and H358 DTPs. Interestingly 
SOX2, which is also known as a regulator of pluripotency98 was upregulated in both PC9 and 
H3122 DTPs but not H358 DTPs. Put together, the findings above may suggest that stem cell 
factors do contribute to the emergence of DTPs, but that the mechanism by which a state of 
enhanced pluripotency is achieved in DTPs is not identical between cell lines. While more 
research is needed in this area, it may be that DTPs adapt and persist treatment with the 
upregulation of only a few stem cell pathways instead of widespread pluripotency factor 
activation being required for drug tolerance.  
 
On the surface it may seem that this supports the hypothesis that random biological noise is 
behind drug tolerance14, 59, driving random expression of genes that may support a pluripotent 
state (as discussed in section 1.5). However, as we consistently saw gene expression patterns 
over multiple biological replicates in each cell line, this hypothesis seems unlikely as each 
individual replicate would have to undergo an identical and highly statistically improbable set 
of random fluctuations in expression. 
 
Instead it may be that each cell line, with its distinct prior evolution and lineage, upregulates 
stem cell factors to ultimately become pluripotent, however how this is achieved in each cell 
line may differ. This supports the findings of a recent research that shows that DTPs arise with 
distinct lineages from a parental population10, 113. This suggests that there is an identical DTP 
program expressed in each biological repeat that leads to a similar pluripotent phenotype, 
however requires a differing set of pluripotency factors to achieve this. Whether this is 
triggered via the inhibition of specific nodes of the MAPK pathway remains unknown and it 
would be interesting to compare different cell lines with identical driver mutations to see if 
they exhibit identical DTP gene expression programs in future experiments.  
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While the involvement of stem cell genes in drug tolerance is certainly not a novel 
phenomenon, we have demonstrated that the mechanism behind this may be more complex 
that first realised, and furthermore occurs in DTPs generated over 72 h in a panel of LUAD 
cell lines. Future research could additionally explore which stem cell factors are activated in 
DTPs arising from different LUAD stable cell lines, and furthermore in different cancer types 
such as melanoma and to identify whether there is a pattern of which stem cells contribute to 
what DTP phenotypes and from what cell of origin. Recent patient data obtained by Maynard 
and colleagues suggests that DTPs upregulate progenitor cell pathways to become increasingly, 
pluripotent, resulting in drug tolerance67. It would be interesting to investigate whether 
alongside changes to progenitor cell genes, stem cell gene upregulation was also present in 
patients in future experiments. From this point it would be interesting to then compare the 
expression of stem cell factors between patient tumour biopsies following ongoing treatment 
to see if stem cell gene expression is variable over time in DTPs present in vivo.  
 
4.5 Drug Tolerant Persisters Enter an AT2-Like Phenotype: 
Following on from the identification that stem cell factors were upregulated in DTPs across 
multiple LUAD cell lines in the present study, we aimed to determine whether a component of 
DTP stemness is their ability to de-differentiate into multipotent progenitor cells, namely the 
highly plastic alveolar-type 2 (AT2) cell. Emerging evidence in melanoma obtained both in 
recent literature60 and by our lab (unpublished) suggests that melanoma DTPs de-differentiate 
to produce a neural crest-like phenotype, the progenitor cell to melanocytes60. Recently, Trevor 
Bivona and colleagues performed scRNAseq on adenocarcinoma biopsies, finding that DTPs 
in patients expressed distinct lineage associated programs, giving them similar gene expression 
profiles to AT2 cells67. With this recent finding in lung cancer samples from patients, and with 
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the knowledge that melanoma cells de-differentiate into their neural crest-like progenitors, we 
aimed to investigate whether LUAD DTPs in our panel of cell lines de-differentiate into an 
AT2-like phenotype.  
 
To this end, we investigated the AT2 markers FOXA2, NKX2-1, SFTPB, SFTPC, SFTPD and 
AQP493-95 (see Table 1 for additional gene information) identified by Maynard and 
colleagues67. We hypothesised that these progenitor cell markers would be expressed at high 
levels in DTPs emerging in LUAD cell line, resulting in an AT2-like multipotent phenotype. 
As done previously, we performed RT-qPCR to investigate the gene expression of AT2 
markers in DTPs rising from LUAD cell lines (Figures 16 and 17).  
 
We found that the surfactant protein genes SFTPC and SFTPD were upregulated consistently 
in DTPs originating from each cell line tested following 72-h drug treatment. This initial 
finding suggests that each cell line in the present study does indeed share a similar expression 
profile to AT2 cells. Interestingly, SFTPB, which was upregulated in PC9 and H358 cells, was 
downregulated in H3122 cells. While SFTPB upregulation in PC9 and H358 cells supports the 
patient data found by Maynard and colleagues67, its downregulation in H3122 cells was 
intriguing.  
 
Unexpectedly FOXA2 and NKX2-1, two prominent markers of AT2 cells in LUAD patients 
with residual disease67, were not detected in PC9 cells prior to and following treatment. This 
was first put down to faulty primers, due to very high cycle threshold (CT) values (30-40 
cycles) or had undetermined CTs for both genes (see Supplementary Tables 1-6). However, 
RT-qPCR using the same primers resulted in detection in both H3122 and H358 cell lines. 
Furthermore, failure to detect FOXA2 and NKX2-1 in PC9 cells was found consistently in each 
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of our 3 biological repeats, while each H358 and H3122 RT-qPCR was successful in analysing 
FOXA2 and NKX2-1, suggesting that this was a biologically significant finding.  
 
Put together, the above evidence suggests that an AT2 phenotype, or at least and AT2-like 
state, was present in the DTP population present in our panel of LUAD cell lines. However, 
due to the unexpected findings found in the present study, this may not be a definitive answer. 
As discussed in the above section (section 4.4), one interpretation of these findings is that DTPs 
are mimicking AT2 lineage cells by upregulating the expression of progenitor genes, however 
it is possible that there is an aspect of redundancy in this development and DTPs arising from 
differing cell lines with distinct backgrounds may utilize different progenitor genes to achieve 
an AT2-like phenotype, becoming increasingly multipotent in the process.  
 
An alternate hypothesis to this may be that DTPs are not mimicking an AT2-like state, but in 
fact originate from AT2 cells themselves. In recent years the notion that NSCLCs originate 
from AT2 cells has gained much popularity, with considerable evidence pointing to a large 
portion of NSCLCs being derived from AT2 cells136-141. Therefore it is likely that the LUAD 
cells used in the present study originated from AT2 cells at the conception of malignancy. 
Following this, it may be that DTP progenitors remain closely linked to their AT2 cell origin, 
while the remainder of the population becomes increasingly genetically and epigenetically 
heterogenous. The concept of branching evolution has been extensively modelled by the likes 
of Gerlinger and colleagues47 and may allow progenitor DTP cells that remain phenotypically 
similar to AT2 cells to evade drug treatment and become tolerant. This concept of branching 
evolution may also explain the differences in gene expression between cell lines as some lines 
remain closer to AT2 cells, while other cells, for example PC9 cells, may lose expression of 
AT2 genes entirely throughout the course of malignancy. One criticism of this hypothesis 
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however is that the majority of the cell-of origin studies outlined above136-138 are limited to 
KRAS mutant LUAD genotypes, and while evidence suggests that other driver mutations may 
also within LUADs may also originate in AT2 cells136-141, further research is clearly required 
to answer this.  
 
Whatever the case, the present study has confirmed that AT2 genes were upregulated in DTPs 
generated in response to a range of targeted agents, pointing to an underlying significance 
waiting to be unlocked. Future studies should investigate further the differences in AT2 
markers involved in DTPs from multiple LUAD line origins to elucidate which genes remain 
common over a larger panel of cell lines. It would also be interesting to determine whether the 
AT2 markers present in DTPs are essential for DTP generation and/or stabilisation or are 
simply artefacts of a gene expression profile based on AT2 cells in order to gain plasticity in 
DTPs. Further study should perform knockout and knockdown studies on the AT2 genes 
involved that we found to be upregulated in DTPs in order to determine this. This is significant 
as isolating whether these genes are essential may allow us to uncover novel drug targets, thus 
having the potential to significantly impact the DTP research field and patients alike.  
 
4.6 AQP4 is a Potential Cell Surface Marker for DTPs in Lung 
Adenocarcinomas:  
With the mechanism behind DTP population generation a topic of significant debate in recent 
years44, we sought to determine whether DTPs are pre-existing or induced upon drug treatment. 
As discussed in section 1.6, there is a large body of evidence for both a pre-existing and 
selection model 9, 12, 44, 59, 60 and for a Lamarckian induction model 8, 10, 11, 14, 61 for generating 
DTPs. To begin to address this question, we aimed to markers specific to the DTP population 
that would allow for isolation of the population via fluorescence activated cell sorting (FACS). 
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This would allow DTPs to be identified in a cell population, allowing for future experiments 
to identify whether the population is present in untreated cells.  
 
The first candidate DTP FACS marker that we investigated was MRAS. MRAS was identified 
as a candidate DTP marker for FACS following gene expression analysis (Dr Euan Rodger, 
unpublished) of an existing RNAseq dataset generated by Jänne and colleagues (GSE 
131594)107. Jänne and colleagues generated DTPs over a 7-day period in a number of LUAD 
cell lines before performing RNAseq to analyze gene expression. Of the genes that were 
differentially expressed between parental and DTP cells, MRAS showed differential expression 
and thus became a candidate for detection via FACS107, 142.  
 
Despite this, we found that both PC9 and H358 cells did not express MRAS differentially in 
DTPs compared to DMSO controls, with no statistical significance found in MRAS expression 
between controls and cells treated with their relevant targeted therapy following analysis via 
RT-qPCR (section 3.5.2). H3122 cells experienced a slight downregulation in MRAS 
expression in DTPs following treatment, however this change was minimal and may not be 
physiologically relevant. Because by Jänne and colleagues generated their DTPs over a period 
of 7-days, it may be possible that MRAS expression only arises following an extended period 
of drug tolerance. This is supported by the findings of previous groups that have proposed that 
there are multiple stages to DTP development and that subpopulations of DTPs arise within 
the DTP population over time59, 113. Further investigation is therefore required to determine 
whether there is a role of MRAS in the emergence of DTPs in vitro in LUAD, however these 
preliminary findings could suggest that future efforts regarding finding markers for DTPs in 
LUAD in order to undergo FACS should be concentrated elsewhere.  
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Aquaporin 4 (AQP4) is a potential candidate DTP cell surface marker and AT2 marker that 
was identified in scRNAseq analysis performed on adenocarcinoma biopsies obtained by 
Trevor Bivona and colleagues67. Given that DTPs adopt an AT2-like phenotype (section 4.4) 
and that AQP4 was upregulated in DTPs in patients67, we hypothesized that its involvement in 
in vitro DTPs and as a universal marker of DTPs in LUAD and that AQP4 may be used as a 
FACS marker given its localization to the cell surface as an aquaporin water transporter87, 143. 
 
We performed RT-qPCR on AQP4 to analyze its gene expression in DTPs in PC9, H3122 and 
H358 cell lines (see section 3.8). We found that AQP4 expression was greatly upregulated in 
each DTP cell type by more than 5-fold, suggesting that AQP4 is indeed a valid candidate on 
which FACS isolation experiments may be performed. Unfortunately, due to time restraints 
and a global COVID-19 pandemic, FACS was unable to be performed on DTPs using AQP4. 
This leaves the opportunity open for future research to attempt to isolate DTPs prior to 
treatment to ascertain for certain whether DTPs are indeed pre-existing or are in fact induced 
upon addition of mutation specific drug. While identifying the origin of DTPs may seem trivial, 
unlocking the mechanisms behind DTP pre-existence and/or induction may lead directly to a 
way of inhibiting the generation of DTPs, thus preventing the formation of resistance and 
relapse in LUAD patients.  
 
It would also be interesting to identify the role of AQP4 in DTPs. While AQP4 is indeed 
upregulated consistently in DTPs originating from multiple lung adenocarcinoma cell line 
models, and in patient samples as shown by Maynard and colleagues67, the role of AQP4 in 
DTPs remains unclear. A novel direction for DTP research may be in investigating the role of 
water channels such as AQP4 in the emergence of drug tolerance and in cancer in general. 
Already a growing body of literature is suggesting the involvement of AQP4 in glioblastoma 
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progression144, 145, suggesting that there may be a significant biological basis for elevated 
expression of AQP4 in DTPs, aside from being an AT2 associated gene, in the emergence of 
DTPs in LUAD. Because of the role of AQP4 in glioblastoma, several AQP4 inhibitors exist, 
and if AQP4 does indeed have a role in the emergence of DTPs, harnessing these existing AQP4 
inhibitors 146-148 could be an interesting prospect for combination therapy alongside targeted 
therapeutics to prevent the emergence drug tolerance. 
 
4.7 Study Limitations: 
A major limitation of the study was the possible effects of cell confluency on cell imaging and 
RT-qPCR based experiments. Both PC9 and H3122 cells were plated at a high density of 
500,000 cells per mL, while H358 cells were plated at 20,000 cells per mL. This led to two 
distinct drawbacks to the study. The first is the direct effects of cell confluency on imaging and 
gene expression analysis. As shown in section 3.3, a large number of cells survive due to the 
high initial density of cells. While this appears to match previous literature8 and the number of 
cells expected given proliferation assay findings (section 3.1) in terms of percent cells 
remaining compared to untreated control, the density of remaining cells is significantly higher 
than previous research8, 49. While unlikely, this may have impacted cell stress given the 
availability of nutrients and space from which to grow in log phase, potentially causing the 
upregulation of stress factors149-151 irrespective of drug treatment that may have altered RT-
qPCR results. Furthermore this high cell density may have had a particular impact on the 
untreated control, from which RT-qPCR was normalised, due to the limited availability of 
nutrients and space to grow unhindered. This may have impacted our findings as the untreated 
controls faced stressful conditions, potentially stimulating them to enter a stressed state, 
altering their gene expression.  
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The second impact of varying cell confluency on the study is the ability to compare PC9 and 
H3122 cells with H358 cells which were plated at a lower cell density. As discussed, cell 
confluency could impact cell stress and expression of cell stress pathways149-151, which has the 
potential to alter RT-qPCR results, and also results in visible changes, hampering our ability to 
compare H358 DTP growth following drug washout in section 3.4. It is important to note 
however that the gene expression of selected markers in H358 cells was similar to PC9 cell 
expression of selected markers, perhaps suggesting that cell confluency may not have altered 
RT-qPCR results dramatically. In any case, future experiments should work to rectify this 
shortcoming, with a lower and consistent cell plating density used between cell lines.  
 
The choice to use proliferation assays to inform drug dosage decisions may also be a limitation 
to the study. While proliferation assays have been used extensively by previous literature in 
the field 8, 11, 12, 113, they may introduce errors into the study. In line with literature, we found 
determining the half maximal inhibitory concentration (IC50) of each cell line treated with its 
respective targeted therapy very difficult. We speculate this this could be due to the SYBR 
Green dye binding non-specifically to apoptotic debris arising from dead and dying cells during 
treatment, thus providing a false reading, particularly around the IC50 mark as many cells 
undergo apoptosis due to treatment. Future experiments should explore more accurate 
measures of cell proliferation, such as staining techniques, to avoid false positives due to 
apoptotic debris in proliferation assays. It is also worth noting that following treatment with 
very low doses of each targeted therapeutic, it appears that there is an increase in cell growth 
as a result. This is particularly apparent when proliferation assays are converted to log scale 
(see Supplementary Figure 1). This is likely due the untreated samples becoming 
overconfluent, resulting in cell death and die back, while cells treated at low doses of drug 
remain initially less confluent, allowing them to outgrow the untreated control over a period of 
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72 hours. This is commonly seen in proliferation and cell viability assays152 and thus was not 
of concern to the integrity of the experiment.  
 
Finally, the use of the term “drug tolerant persister” may be a limitation, not only to the study, 
but to the field of DTP research. The term “drug tolerant persisters” has become somewhat of 
a blanket term for cells persisting during drug treatment without the presence of stable 
resistance mutations. While this description accurately portrays the biology occurring, it may 
limit future research by leading researchers to assume that each “DTP” population isolated in 
each study is identical. While this may be the case, in reality it is also likely that the 
development of drug tolerance maybe more complex. Although there may be similarities, such 
as reverting to a progenitor state, the ways in which the cell survives drug treatment may differ 
dramatically between DTPs in each study in events similar to the emergence of bypass 
mutations that permit resistance. The present study often assumes that previous findings found 
in DTPs in LUAD and other cancers, in patient and in vitro cells, apply to a universal concept 
of DTPs, a fact yet to be proven, thus limiting our ability to consider mechanisms of tolerance 
unique to a particular scenario. This is assumption is not limited to this study and persists in 
many recent publications to date13, 49, 75, 153, 154.  
 
4.8 Future Directions 
Given the findings of the present study and recent literature, scope for future research into 
DTPs, their emergence and their inhibition is enormous. As outlined above, much research is 
needed to understand the principles that underpin our results and the findings of recent 
literature. Furthermore, exploring novel angles such as adaptive mutability, the role of long 
non-coding RNA (lncRNAs), and novel therapeutic approaches provide excellent opportunities 
for furthering our understanding of DTPs and how to prevent their emergence in patients.  
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4.8.1 Investigating Adaptive Mutability in DTPs: 
One of the hallmarks of drug tolerance is a shift toward stable resistance over time155, 156, 
causing relapse and preventing patients from responding to further treatment. This appears to 
be largely caused by adaptive mutagenesis, the process by which replication becomes error-
prone, resulting in rapid genetic adaption caused by the selection of cells containing mutations 
that confer drug resistance8, 110. 
 
To date, very limited research underpins our understanding of the progression from the 
reversible and fluid mechanisms of drug tolerance to a stable drug resistance phenotype 155, 156. 
Moreover, our understanding the dynamic between epigenetic and genetic adaptations toward 
stable resistance remains limited8, 11, 14, 110. Future studies should focus on how DTPs transition 
from tolerance into stable resistance and the mechanisms that underpin their adaptive 
mutability.  
 
In the first instance it would be interesting to examine the presence of genome instability found 
in DTPs. This could be achieved using dual AQP4 (isolated to be a cell surface marker of DTPs 
in the present study)/γH2AX staining. γH2AX is a marker for double stranded breaks and 
genome instability and has previously been used in DTPs157. It would then be interesting to 
perform RNA-seq on the AQP4HIGH/γH2AXHIGH population to identify possible pathways that 
may contribute to adaptive mutability. 
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4.8.2 lncRNAs in Drug Tolerance: 
Emerging in recent literature, long non-coding RNAs (lncRNAs) could be major players in 
modulating the adaptive mutability of DTPs158-163. Interestingly, it is well known that many 
lncRNAs contribute to genetic instability164-166 and furthermore, several pathways determined 
to be essential both in DTPs and adaptive mutagenesis, including the Hippo and mTOR 
pathways13, 155, 156, 167, are highly regulated by lncRNAs164, 165. Furthermore, lncRNAs are also 
known to cause genetic instability by stalling the replication fork, resulting in error-prone 
replication restart166. To investigate this, performing RNA-seq on the AQP4HIGH/γH2AXHIGH 
population explained above may outline potential lncRNA candidates from which future 
research could take place.  
 
The present study has outlined the possibility that DTPs in LUAD de-differentiate into 
progenitor lung cell phenotypes that allow them to gain plasticity. it is well known that many 
lncRNAs also regulate the processes that underpin plasticity158-162, 168. Thus, in addition to 
having roles in adaptive mutability, it would be interesting to investigate the role of lncRNAs 
in DTP plasticity and pluripotency. One such lncRNA, H19, is known to regulate the stem cell 
markers CD133, NANOG, OCT3/4, and SOX2158. SOX2 itself appears to be highly regulated 
by lncRNAs. For example the lncRNAs SOX2OT159, 160, NEAT1161, and MALAT1162 all 
regulate SOX2. Interestingly, lncRNAs such as NEAT1 and MALAT1 theselves appear to be 
regulated directly by other stem cell factors, including OCT4, in lung cancers168. 
 
This direction may also offer a novel method of DTP treatment, with antisense oligonucleotides 
being suitable for downregulating lncRNAs that are retained in the nucleus by inducing RNase-
H mediated cleavage of lncRNAs and premature termination of lncRNA transcription169-171. 
More novel therapeutic strategies, such as expression modulation via CRIPSR-Cas 
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activation172, inhibition173, or even direct RNA degradation174, systems are readily being 
explored for lncRNA modulation due to the ability of CRISPR-Cas to rapidly and precisely 
modulate expression171-174. Already, this relatively new technology has been used to 
knockdown MALAT1, with reductions in gene expression of up to 98%175, highlighting 
significant and untapped therapeutic opportunities present in this field if lncRNAs are proven 
to be involved in the emergence of drug tolerance.  
 
4.8.3 Past, Present, and Future Potentials for DTP Therapy: 
While many future directions lie in the above discussion, a focus on utilizing what we know to 
target the emergence of DTPs should be taken. Despite very little being known about DTPs, 
this now decade old field has generated a large number of possible therapeutic potentials that 
have not yet been properly evaluated. While certainly not a comprehensive list, the current 
focus for therapeutically inhibiting the emergence of DTPs lies both in inhibiting the epigenetic 
underpinning of DTPs and the inherent vulnerability of DTPs to oxidative stress.  
 
Early on, Sharma and colleagues determined that DTPs are dependent on the histone 
demethylase KDM5A/RBP2/Jarid1A (referred to as simply KDM5)8 (top of Figure 18). KDM5 
is one of the factors that mediates phenotypic transition toward a slow cycling phenotype 
through removing the repression of H3K4 methylation on cell-cycle related genes, and thus 
inhibiting KDM5, would theoretically inhibit DTP formation8. Since this discovery, several 
attempts have been made to inhibit KDM5 function via the IGF-1R inhibitor AEW5418, histone 
deacetylase (HDAC) inhibition8 and more recently through the direct KDM5 inhibitor CPI-
445176. However, as yet no treatment has found the required potency or safety to move forward 
into the clinic.  
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In addition to preventing the KDM5 mediated phenotypic shift in DTPs, HDAC inhibition 
results in the reversal of H3K9me3-mediated heterochromatin formation over long interspersed 
nuclear elements (LINEs), and in particular over LINE-1177. A lack of H3K9me3-mediated 
repression of LINE-1 results in the transcription of its open reading frame 2 (ORF2) which 
codes for reverse transcriptase177. This allows for the movement of retrotransposons such as 
LINE-1 and other transposable elements throughout the genome of DTPs, resulting in global 
genome damage that depletes the DTP population177. 
 
In addition to being vulnerable to KDM5 inhibition, DTPs show an enhanced sensitivity to 
redox stress (bottom of Figure 18)13, 49, 72, 153. DTPs contain a global reduction in redox 
regulators such as loss of nuclear factor erythroid 2-related factor 2 (NRF2) signaling49. The 
result of this is a dramatic loss of expression of reducing compounds such as NADPH and 
glutathione that allow the cell to respond to redox stress, making them highly dependent on 
remaining redox regulators such as glutathione peroxidase 4 (GPX4)49, cystine-glutamate 
antiporter (xCT)153 and aldehyde dehydrogenase (ALDH)13, 51, 72 to protect themselves from 
oxidative stresses (see Figure 18). Given the precarious redox balance position of DTPs, 
dysregulation of one of these redox responders causes an immense vulnerability of DTPs to 
redox damage, lipid peroxidation and death via ferroptosis49, 72, 153, allowing for a unique 






Figure 18: Targeting the intrinsic vulnerabilities of DTPs. Inhibition of epigenetic adaptation (above) 
both inhibits the KDM family of histone demethylases, thus repressing phenotype transition, and 
induces expression of transposons that cause global genome destruction, leading to death of DTPs. 
Additionally, DTPs are vulnerable to redox dysregulation (above) due to a global loss of antioxidant 
regulators such as NRF2. This forces DTPs to rely on remaining redox effectors such as GPX4, xCT 
and ALDH to protect from oxidative damage. Thus loss of these effectors results in reduction in DTP 
formation. Image created using BioRender.com. Original work, Davis 2021. 
 
Despite an initial arms race to exploit this apparent weakness in DTPs, no inhibitors have been 
found to be safe and clinically effective in ablating the DTP population via redox damage. 
However, a recent focus on inhibition of GPX4 with the GPX4 inhibitors RSL3 and ML210 
has seen been initially successful49, 178, particularly when used in combination with as 
dihydroorotate dehydrogenase (DHODH) inhibitors178. DHODH acts as a redundancy 
mechanism to rescue cells given GPX4 KO, and as a result combination therapy saw a total 
ablation of the DTP population178. 
 
Given the findings of the present study, future experiments should investigate further the role 
of stem and progenitor cell genes and look into whether inhibition of these pathways prevents 
the emergence of drug tolerance. Existing therapeutics that target pluripotency, such as 
TTFD179 and metformin180, as well as therapies that target lung progenitor genes, such as the 
AQP4 inhibitor trifluoperazine, may hold the key to ablating DTPs in LUAD when used in 




4.9  Conclusions: 
In summary, we have demonstrated that DTPs emerge in PC9, H3122 and H358 lung cancer 
cell lines which contain oncogenic mutations in EGFR, ALK and KRAS, respectively, 
following treatment with targeted therapy. We show that the MAPK pathway is inhibited prior 
to the emergence of PC9 DTPs and that following drug washout, colonies of cells are able to 
emerge from DTPs. Significantly, we show that DTPs upregulate stem cell and lung progenitor 
cell genes, suggesting that they adopt an AT2 -like phenotype to evade therapy (Figure 19). As 
discussed, this study did provide several limitations, such as cell confluency, that limited the 
study, however our findings open up the opportunity to explore a plethora of novel avenues 
while better equipping future researchers to do so with markers of drug tolerance such as 
AQP4. Furthermore, this research has isolated the need to explore therapeutic novel therapeutic 
avenues such as inhibiting pluripotency and AT2-cell genes as discussed above (section 4.8.3).  
 
 
Figure 19: Stem cell and progenitor cell are differentially expressed in the DTP population, 
suggesting their involvement in the emergence of DTPs in LUAD. Image created using 
BioRender.com. Original work, Davis 2021 
 
The elucidation of the mechanisms that underpin DTPs, and possible therapeutics, is not 
limited to lung cancers; other cancer types, such as glioblastoma12 and melanoma181 also 
exhibit the emergence of DTPs following treatment. This extends the significance of the 
findings reported in the present study to our understanding of drug tolerance not only in LUAD, 
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but in other cancer types as well. Cancer is the second highest cause of mortality on the planet, 
second only to heart disease. Research into the mechanisms that underpin the biology of 
cancers and why they persist despite treatment therefore has the potential to impact millions 
worldwide, both overseas and in New Zealand3, 4. While there is much work to do, the 
knowledge gained in this project has allowed us to find future directions from which to 
investigate the phenomenon of drug tolerance.  
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Appendix I: Reagents: 
Reagent Brand Catalogue 
Number 
1 kb protein ladder BioRad 1610374 
2X Sybr Mix TB Green Premix Ex Taq II 
(Tli RNase H Plus) 
Takara 4309155) 
4-20% Mini-PROTEAN TGXTM 
Precast Protein Gels, 12-well, 
BioRad  4561095 
Anti-histone H3 Sigma-Aldrich H0164-25UL 
Anti-p44/42 MAPK (ERK) Cell Signalling 
Technology 
9102 
Anti-phospho-p44/42 MAPK (pERK) Cell Signalling 
Technology 
9101 
Beta-mercaptoethanol ThermoFisher Scientific 21985023 
cOmplete, Mini, EDTA-free Protease 
Inhibitor Cocktail 
Roche 4693159001 
Crizotinib (PF-02341066) Selleckchem S1068 
Crystal violet stain  Sigma-Aldrich C0775 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D8418-100ML 
EDTA ThermoFisher Scientific 15576028 
Foetal bovine-serum (FBS) Moregate 10091130 
GlutaMAX RPMI-1640 growth 
medium 
ThermoFisher Scientific 61870036 
Glycerol ThermoFisher Scientific 17904 
Glycine Reagent Plus, ≥99% (HPLC) Sigma-Aldrich G7126 
 
IRDye 680RD Goat anti-Rabbit IgG 
Secondary Antibody 
LI-COR 926-68071 
Low ROX Takara 12223012 
Methanol ThermoFisher Scientific A452SK-4 
Mycoalert Mycoplasma test Kits Lonza LT07-118 
NaCl ThermoFisher Scientific S-3160-70 
Nitrocellulose membrane BioRad 1620112 
NP-40 Surfact-Amps Detergent 
Solution 
Thermo-Fisher Scientific 85124 
Osimertinib (AZD9291) Selleckchem S7297 
phosphate buffered saline (PBS) ThermoFisher Scientific 18912014 
Pierce BCA Protein Assay Kit ThermoFisher Scientific 23225 
PureLink RNA Mini Kit Ambion by Life 
Technologies 
12183018A 
qScript cDNA Supermix Quantabio 95048-100 
RPMI-1640 ATCC ATCC-30-2001 
Sodium deoxycholate ThermoFisher Scientific 89904 
Sodium Dodecyl Sulfate (SDS), C12 ThermoFisher Scientific 28312 
 97 
Sotorasib (AMG510) Selleckchem S8830 
SYBR Green 1 ThermoFisher Scientific S-7563 
SYBR Green I Nucleic Acid Gel Stain ThermoFisher Scientific S7563 
TBS Blocking Buffer LI-COR 927-60001 
Tris-Base ThermoFisher Scientific 15506017 
Triton X-100 Sigma-Aldrich X100-500ML 
trypan blue Sigma-Aldrich T8154 
trypsin (0.25% v/v) with phenol red ThermoFisher Scientific 15050065 
TWEEN 20 viscous liquid Sigma-Aldrich P1379-500ML 
UltraPure Tris Buffer (powder format) ThermoFisher Scientific 15504020 
UltraPure Tris Hydrochloride ThermoFisher Scientific 15506017 
 
 
Appendix II: Buffer Recipes:  
Cell Lysis Buffer:  
Reagent  
Tris-HCl at pH 8.0 10 mM 
EDTA 2.5 mM 
TritonX-100 1% (v/v) 
 
2x Radioimmunoprecipitation Assay (RIPA) Buffer Preparation: 
Reagent per 50 mL 2x RIPA 
NaCl 300 mM 
NP40 2% (v/v) 
Sodium deoxycholate 1% (v/v) 
SDS  0.20% (v/v) 
Tris  50 mM 
Milli-Q H2O Up to 50 mL 
 
4x Laemmli Buffer: 
Reagent per 50 mL 4x 
Laemmli Sample Buffer 
Amount to Add 
Tris (1M, pH 6.8) 10 mL 
Glycerol 20 mL 
SDS 4g 
Milli-Q H2O Up to 50mL 
 
Electrophoresis Buffer:  
Reagent per 1L 4x 
Electrophoresis Buffer 






Transfer Buffer (1L):  
Reagent per 1L 
Transfer Buffer 
Amount to Add  
Glycine 14.4g 
Tris-base 3g 
Methanol 200 mL 
dH20 Up to 1L 
 
10x TBS:  
Reagent per 1L 10x TBS 
(pH to 7.6) 




TBS-Tween 0.1% (TBS-T): 






Tween 20 1 
 
Blocking Buffer:  
Reagent Volume Added 
Licor TBS Blocking Buffer 30 mL 











Appendix III: Primer Sequences:  
Gene Target Primer Name Primer Sequence (5’ to 3’) 
























































Supplementary Figure 1: Proliferation assays with the X-Axis Plotted Log10. A shows PC9 
proliferation assay (n=3), B shows H3122 proliferation assay (n=3), C shows H358 proliferation 
assay (n=3) and D shows LL2 proliferation assay (n=1). Error bars represent standard deviations 
from the mean. 






































































































Supplementary Figure 2: Full Western blots for ERK (left) and pERK (right) on PC9 cells treated 
from left to right with DMSO, 2 µM osimertinib, 5 µM osimertinib, and 10 µM osimertinib. N=1. 
 
Supplementary Figure 3: Full Western blots for Histone H3. Left was run on the ERK blot on PC9 
cells treated from left to right with DMSO, 2 µM osimertinib, 5 µM osimertinib, and 10 µM 
osimertinib.. Right was run on the pERK blot with identical drug treatments. Histone H3 was run on 
the above blots found in Supplementary Figure 2 sequentially. Additional bands are due to residual 


































































































Supplementary Figure 4: Expression of OCT3/4 (A), NANOG (B), SOX2 (C), MRAS (D), AQP4 (E), 
FOXA2 (F), NKX2-1 (G), SFTPB (H), SFTPC (I), and SFTPD (J) analysed by RT-qPCR analysis in 
PC9 cells treated with the indicated treatment. Each experiment was performed 3 times (n=3). Error 
bars represent standard deviations from the mean. ns=not significant, *=P ≤ 0.05, **=P ≤ 0.01, ***=P 

























































































































































































































































































































































































































































































































































Supplementary Figure 5: Expression of OCT3/4 (A), NANOG (B), SOX2 (C), MRAS (D), AQP4 (E), 
FOXA2 (F), NKX2-1 (G), SFTPB (H), SFTPC (I), and SFTPD (J) analysed by RT-qPCR analysis in 
H3122 cells treated with the indicated treatment. Each experiment was performed 3 times (n=3). Error 
bars represent standard deviations from the mean. ns=not significant, *=P ≤ 0.05, **=P ≤ 0.01, ***=P 









































































































































































































































































































































































































































Supplementary Figure 6: Expression of OCT3/4 (A), NANOG (B), SOX2 (C), MRAS (D), AQP4 (E), 
FOXA2 (F), NKX2-1 (G), SFTPB (H), SFTPC (I), and SFTPD (J) analysed by RT-qPCR analysis in 
H358 cells treated with the indicated treatment. Each experiment was performed 3 times (n=3). Error 
bars represent standard deviations from the mean. ns=not significant, *=P ≤ 0.05, **=P ≤ 0.01, ***=P 
≤ 0.001, ****=P ≤ 0.0001. 
 
Supplementary Table 4: First repeat raw CT values following RT-qPCR for FOXA2 following 72-h 
treatment with osimertinib at 2 µM, 5 µM or 10 µM. DMSO treated cells were provided as a control. 
DMSO 2 µM 5 µM 10 µM 
Undetermined 33.787 32.627 Undetermined 
34.159 33.923 Undetermined 34.696 
Undetermined 35.385 34.840 34.696 
 
Supplementary Table 5: First repeat raw CT values following RT-qPCR for NKX2-1 following 72-h 
treatment with osimertinib at 2 µM, 5 µM or 10 µM. DMSO treated cells were provided as a control. 
DMSO 2 µM 5 µM 10 µM 
Undetermined Undetermined 35.208 Undetermined 
Undetermined Undetermined Undetermined Undetermined 













































































































































































Supplementary Table 6: Second repeat raw CT values following RT-qPCR for FOXA2 following 72-h 
treatment with osimertinib at 2 µM, 5 µM or 10 µM. DMSO treated cells were provided as a control. 
DMSO 2 µM 5 µM 10 µM 
36.324 Undetermined 33.851 33.709 
34.956 33.100 36.867 35.445 
35.074 38.283 35.244 Undetermined 
 
Supplementary Table 7: Second repeat raw CT values following RT-qPCR for NKX2-1 following 72-h 
treatment with osimertinib at 2 µM, 5 µM or 10 µM. DMSO treated cells were provided as a control. 
DMSO 2 µM 5 µM 10 µM 
37.933 31.870 33.118 34.375 
34.952 34.000 34.352 37.846 
38.036 33.287 Undetermined Undetermined 
 
Supplementary Table 8: Third repeat raw CT values following RT-qPCR for FOXA2 following 72-h 
treatment with osimertinib at 2 µM, 5 µM or 10 µM. DMSO treated cells were provided as a control. 
DMSO 2 µM 5 µM 10 µM 
35.389 Undetermined Undetermined Undetermined 
Undetermined 38.480 38.822 33.965 
Undetermined 36.681 33.962 Undetermined 
 
Supplementary Table 9: Third repeat raw CT values following RT-qPCR for NKX2-1 following 72-h 
treatment with osimertinib at 2 µM, 5 µM or 10 µM. DMSO treated cells were provided as a control 
DMSO 2 µM 5 µM 10 µM 
37.041 Undetermined Undetermined Undetermined 
37.341 Undetermined 34.652 Undetermined 
Undetermined Undetermined 34.148 Undetermined 
 
 
